HEMATOLOGY SHORT NOTES

Concise Review for Doctors & Medical Students



1ST EDITION

RISHAD THAHIR

Title: Hematology Short Notes : Essential Guide for Doctors and Medical Students
Edition : First Edition
Author: Dr. Rishad Thahir
Publisher: Rish Academy

RISHACADEMY
educate yourself to empower yourself

Disclaimer
The information provided in this book is for academic purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment.

Acknowledgments
I would like to express my deepest gratitude to my colleagues and mentors who provided invaluable insights and support throughout the writing process. Special thanks to Dr. Mashrifa for her thorough review and constructive feedback. I also extend my heartfelt thanks to my family for their patience and understanding.

Chapters

1. Red Blood Cell Disorders

- **Anemias**
  - Iron Deficiency Anemia
  - Vitamin B12 Deficiency Anemia (Pernicious Anemia)
  - Folate Deficiency Anemia
  - Hemolytic Anemia
  - Sickle Cell Anemia
  - Thalassemias (Alpha and Beta)
  - Aplastic Anemia
  - Anemia of Chronic Disease
- **Hemoglobinopathies**
  - Sickle Cell Disease
  - Thalassemias
  - Hemoglobin C Disease
  - Hemoglobin E Disease
- **Other RBC Disorders**
  - Polycythemia Vera
  - Hereditary Spherocytosis
  - G6PD Deficiency
  - Paroxysmal Nocturnal Hemoglobinuria (PNH)

2. White Blood Cell Disorders

- **Leukemias**
  - Acute Lymphoblastic Leukemia (ALL)
  - Acute Myeloid Leukemia (AML)
  - Chronic Lymphocytic Leukemia (CLL)
  - Chronic Myeloid Leukemia (CML)
- **Lymphomas**
  - Hodgkin's Lymphoma
  - Non-Hodgkin's Lymphoma
- **Plasma Cell Disorders**
  - Multiple Myeloma
  - Waldenström's Macroglobulinemia
  - Monoclonal Gammopathy of Undetermined Significance (MGUS)
- **Other WBC Disorders**
  - Neutropenia
  - Lymphocytosis
  - Eosinophilia
  - Myelodysplastic Syndromes (MDS)
  - Chronic Granulomatous Disease

3. Platelet Disorders

- **Thrombocytopenia**
  - Immune Thrombocytopenic Purpura (ITP)
  - Thrombotic Thrombocytopenic Purpura (TTP)
  - Heparin-Induced Thrombocytopenia (HIT)
  - Disseminated Intravascular Coagulation (DIC)
- **Thrombocytosis**
  - Essential Thrombocythemia
- **Qualitative Platelet Disorders**
  - Bernard-Soulier Syndrome
  - Glanzmann's Thrombasthenia

4. Coagulation Disorders

- **Hemophilia**
  - Hemophilia A (Factor VIII Deficiency)
  - Hemophilia B (Factor IX Deficiency)
- **Von Willebrand Disease**
  - Type 1
  - Type 2 (A, B, M, N)
  - Type 3
- **Acquired Coagulation Disorders**
  - Liver Disease
  - Vitamin K Deficiency
  - Anticoagulant Therapy (Warfarin, Heparin)
- **Thrombophilia**
  - Factor V Leiden
  - Prothrombin Gene Mutation
  - Antithrombin Deficiency
  - Protein C and S Deficiency
  - Antiphospholipid Syndrome

5. Bone Marrow Disorders

- **Aplastic Anemia**
- **Myeloproliferative Disorders**
  - Polycythemia Vera
  - Essential Thrombocythemia
  - Myelofibrosis
  - Chronic Myeloid Leukemia (CML)
- **Myelodysplastic Syndromes (MDS)**
- **Paroxysmal Nocturnal Hemoglobinuria (PNH)**

6. Hematologic Malignancies

- **Leukemias**
- **Lymphomas**
- **Multiple Myeloma**
- **Myelodysplastic Syndromes**
- **Myeloproliferative Neoplasms**

7. Transfusion Medicine

- **Transfusion Reactions**
  - Hemolytic Transfusion Reactions
  - Febrile Non-Hemolytic Transfusion Reactions
  - Allergic Reactions
  - Transfusion-Related Acute Lung Injury (TRALI)
  - Transfusion-Associated Circulatory Overload (TACO)
- **Blood Component Therapy**
  - Red Blood Cell Transfusion
  - Platelet Transfusion
  - Plasma Transfusion
  - Cryoprecipitate Transfusion

8. Hemoglobin Disorders

- **Thalassemias**
- **Sickle Cell Disease**
- **Hemoglobin C Disease**
- **Hemoglobin E Disease**

1 Red Blood Cell Disorders

- Anemias
  - Iron Deficiency Anemia
  - Vitamin B12 Deficiency Anemia (Pernicious Anemia)
  - Folate Deficiency Anemia
  - Hemolytic Anemia
  - Sickle Cell Anemia
  - Alpha Thalassemias
  - Beta Thalassemias
  - Aplastic Anemia
  - Anemia of Chronic Disease
- Hemoglobinopathies
  - Sickle Cell Disease
  - Hemoglobin C Disease
  - Hemoglobin E Disease
- Other RBC Disorders
  - Polycythemia Vera
  - Hereditary Spherocytosis
  - G6PD Deficiency
  - Paroxysmal Nocturnal Hemoglobinuria (PNH)

Iron Deficiency Anemia

Definition

Iron Deficiency Anemia (IDA) is a microcytic, hypochromic anemia caused by insufficient iron, leading to inadequate hemoglobin synthesis.

Etiology

- **Dietary deficiency**: Inadequate intake of iron-rich foods (e.g., vegetarian diets)
- **Increased demand**: Pregnancy, lactation, growth spurts in children
- **Chronic blood loss**: Gastrointestinal bleeding (e.g., peptic ulcer, malignancies), menstrual bleeding
- **Malabsorption**: Celiac disease, gastric surgery (e.g., gastrectomy, bariatric surgery)

Pathophysiology

- Iron is essential for hemoglobin synthesis. Deficiency results in reduced erythropoiesis and smaller, hypochromic red blood cells.
- **Stages**:
  1. **Depletion of iron stores**: Decreased ferritin, normal RBC indices
  2. **Iron-deficient erythropoiesis**: Reduced serum iron, increased total iron-binding capacity (TIBC)
  3. **Iron deficiency anemia**: Microcytic, hypochromic RBCs, reduced hemoglobin

Clinical Features

- **General symptoms**: Fatigue, pallor, weakness, dyspnea on exertion
- **Specific symptoms**: Pica (craving for non-food substances), angular stomatitis, koilonychia (spoon-shaped nails)
- **In severe cases**: Tachycardia, glossitis

Diagnosis

- **Blood tests**:
  - Hemoglobin: Low
  - MCV (Mean Corpuscular Volume): Low (microcytic)
  - MCH (Mean Corpuscular Hemoglobin): Low (hypochromic)
  - Serum ferritin: Low (most sensitive early indicator)
  - Serum iron: Low
  - TIBC: Elevated
  - Transferrin saturation: Low
- **Peripheral blood smear**: Microcytic, hypochromic RBCs
- **Bone marrow biopsy**: Absent iron stores (rarely indicated)

Differential Diagnosis

- Anemia of chronic disease
- Thalassemia
- Sideroblastic anemia

Management

Identify and treat the underlying cause:

- Control bleeding, address malabsorption, or improve diet.

Iron supplementation:

- **Oral iron**: Ferrous sulfate (325 mg) 1-3 times/day for 3-6 months; side effects include GI upset, constipation.
- **Intravenous iron**: Indicated for malabsorption, intolerance to oral iron, or severe deficiency (e.g., ferric carboxymaltose).

Dietary advice:

- Increase intake of iron-rich foods (e.g., red meat, beans, fortified cereals) and vitamin C to enhance absorption.

Blood transfusion:

Reserved for symptomatic severe anemia or cardiac compromise.

Monitoring

- Reticulocyte count increases in 1-2 weeks after starting treatment.
- Hemoglobin normalization in 6-8 weeks; continue iron therapy for 3-6 months to replenish stores.

Complications

- Delayed growth and cognitive development in children
- Pregnancy complications: Preterm delivery, low birth weight
- Cardiac failure in severe anemia

Vitamin B12 Deficiency Anemia (Pernicious Anemia)

Definition

A type of macrocytic anemia caused by insufficient absorption of Vitamin B12, commonly due to autoimmune destruction of gastric parietal cells (pernicious anemia) or dietary deficiency.

Causes

- **Autoimmune**: Pernicious anemia (antibodies against intrinsic factor or gastric parietal cells).
- **Dietary**: Vegan or vegetarian diets, malnutrition.
- **Gastrointestinal disorders**: Atrophic gastritis, Crohn's disease, celiac disease, gastrectomy, ileal resection.
- **Medications**: Proton pump inhibitors, metformin.

Pathophysiology

- **B12 Absorption**: Requires intrinsic factor (IF) produced by gastric parietal cells.
- **Pernicious Anemia**: Autoimmune destruction of parietal cells → decreased IF → impaired absorption of B12 in the ileum → megaloblastic anemia.

Clinical Features

- **General**: Fatigue, weakness, pallor.
- **Neurological**: Peripheral neuropathy, paresthesia, ataxia, cognitive disturbances (due to demyelination of nerves).
- **GI**: Glossitis, diarrhea, loss of appetite, weight loss.
- **Hematologic**: Megaloblastic anemia (macrocytic), thrombocytopenia, neutropenia.

Diagnostic Workup

- **CBC**: Macrocytic anemia, low hemoglobin, elevated MCV (>100 fL).
- **Peripheral Smear**: Hypersegmented neutrophils, macrocytes.
- **Serum B12 Levels**: Low (<200 pg/mL).
- **Serum Methylmalonic Acid & Homocysteine**: Elevated (more specific for B12 deficiency).
- **Anti-Intrinsic Factor and Anti-Parietal Cell Antibodies**: Positive in pernicious anemia.
- **Schilling Test** (rarely used): To assess B12 absorption.

Treatment

Vitamin B12 Supplementation:

- Intramuscular (IM) injections of cyanocobalamin or hydroxocobalamin.
- Oral B12 (high-dose) if absorption is intact.

Maintenance Therapy:

Lifelong B12 supplementation in pernicious anemia.

Neurological Symptoms: May be irreversible if not treated early.

Complications

- **Neurological**: Irreversible nerve damage, dementia.
- **Hematologic**: Pancytopenia if severe.
- **Gastrointestinal**: Increased risk of gastric cancer in pernicious anemia.

Follow-up

- Monitor CBC and B12 levels regularly.
- Neurological symptoms should be closely monitored for improvement.

Folate Deficiency Anemia

Definition

A macrocytic anemia caused by a deficiency of folate (Vitamin B9), leading to impaired DNA synthesis in red blood cells.

Etiology

- **Dietary deficiency:** Inadequate intake of folate (e.g., poor diet, alcoholism).
- **Malabsorption:** Conditions such as celiac disease, Crohn's disease, or short bowel syndrome.
- **Increased demand:** Pregnancy, hemolytic anemia, and malignancy.
- **Drugs:** Methotrexate, trimethoprim, phenytoin, sulfasalazine.
- **Chronic alcoholism:** Impairs folate absorption and storage.

Pathophysiology

- Folate is required for DNA synthesis, particularly in rapidly dividing cells like red blood cells.
- Deficiency leads to ineffective erythropoiesis, resulting in the production of large, immature red blood cells (megaloblasts).

Clinical Features

- Fatigue, pallor, weakness.
- Glossitis, stomatitis.
- No neurological symptoms (in contrast to Vitamin B12 deficiency).
- Symptoms related to underlying causes (e.g., malabsorption).

Laboratory Findings

- **CBC:** Macrocytic anemia (MCV >100 fL), hypersegmented neutrophils.
- **Low serum folate levels** (normal: 5-15 ng/mL).
- **Low RBC folate** (reflects tissue stores).
- **Normal Vitamin B12 levels** (to differentiate from B12 deficiency anemia).
- **Increased homocysteine levels.**

Management

- **Folic acid supplementation:** Oral folic acid 1-5 mg/day.
- **Dietary modification:** Increase intake of folate-rich foods (leafy greens, citrus fruits, legumes).
- **Treat underlying cause** (e.g., malabsorption, alcoholism).
- **Prophylaxis in high-risk groups**: Pregnant women, hemolytic anemias, malabsorption syndromes.

Diagnosis

- Based on clinical suspicion, confirmed by laboratory findings (low serum and RBC folate levels).
- Exclude other causes of macrocytic anemia (e.g., Vitamin B12 deficiency).

Complications

- Megaloblastic anemia.
- Neural tube defects in pregnancy (if folate deficiency is present during pregnancy).

Prevention

- Folic acid supplementation in pregnancy.
- Dietary fortification programs in certain countries.

Hemolytic Anemia

Definition

Hemolytic anemia is a condition characterized by the premature destruction of red blood cells (RBCs), leading to anemia. The bone marrow increases RBC production to compensate, but it may not be sufficient to maintain normal hemoglobin levels.

Classification

1. **Intrinsic (intracorpuscular)** - Defects within the RBCs.
   - ***Hereditary*:**
     - Membrane defects (e.g., hereditary spherocytosis, elliptocytosis)
     - Enzyme deficiencies (e.g., G6PD deficiency, pyruvate kinase deficiency)
     - Hemoglobinopathies (e.g., sickle cell disease, thalassemias)
   - ***Acquired*:** Paroxysmal nocturnal hemoglobinuria (PNH)
2. **Extrinsic (extracorpuscular)** - External factors cause RBC destruction.
   - ***Immune-mediated*:** Autoimmune hemolytic anemia (AIHA), alloimmune hemolysis (e.g., hemolytic disease of the newborn)
   - ***Non-immune*:** Mechanical (e.g., microangiopathic hemolytic anemia), infections (e.g., malaria), drugs, toxins

Pathophysiology

- RBC destruction occurs either intravascularly or extravascularly (primarily in the spleen and liver).
- Intravascular hemolysis: RBCs rupture within the blood vessels, releasing hemoglobin directly into the bloodstream.
- Extravascular hemolysis: Macrophages in the spleen and liver phagocytose defective or opsonized RBCs.

Clinical Features

- Pallor, fatigue, jaundice (from increased bilirubin)
- Dark urine (hemoglobinuria, hemosiderinuria)
- Splenomegaly
- Gallstones (due to chronic hemolysis)
- In severe cases: shortness of breath, tachycardia, heart failure

Laboratory Findings

- **Blood tests**: Decreased hemoglobin, reticulocytosis, increased lactate dehydrogenase (LDH), elevated indirect bilirubin
- **Peripheral smear**: Schistocytes (fragmented RBCs) in intravascular hemolysis; spherocytes in extravascular hemolysis
- **Coombs test**:
  - Direct Coombs test positive in autoimmune hemolysis
  - Indirect Coombs test can detect alloimmune causes
- **Haptoglobin**: Decreased (binds free hemoglobin in intravascular hemolysis)
- **Urinalysis**: Hemoglobinuria, hemosiderinuria

Management

- **Treat the underlying cause**: Infection, autoimmune disorder, etc.
- **Supportive care**: Blood transfusions if necessary
- **Steroids**: For immune-mediated hemolysis (e.g., AIHA)
- **Immunosuppressants**: For refractory cases
- **Splenectomy**: In chronic cases or those unresponsive to other treatments
- **Folic acid supplementation**: To support increased RBC production
- **Avoidance of triggers**: In hereditary conditions like G6PD deficiency

Complications

- Chronic hemolysis can lead to anemia, gallstones, iron overload, and increased risk of infections (especially post-splenectomy).

Key Points

- Hemolytic anemia can be hereditary or acquired.
- Diagnosis involves a combination of clinical features, laboratory findings, and specific tests (e.g., Coombs test).
- Treatment varies depending on the cause, with immunosuppressive therapy or splenectomy indicated in severe or refractory cases.

Sickle Cell Anemia

Definition

Sickle Cell Anemia is an inherited hemoglobinopathy caused by a mutation in the β-globin gene (HBB), resulting in abnormal hemoglobin (HbS) that leads to red blood cell deformation into a sickle shape under hypoxic conditions.

Genetics

- Autosomal recessive disorder.
- Homozygous HbSS leads to sickle cell disease (SCD), while heterozygous (HbAS) is sickle cell trait (asymptomatic or mild symptoms).

Pathophysiology

- **HbS polymerization**: Under deoxygenation, HbS polymerizes, causing RBCs to deform into sickle shapes.
- **Vaso-occlusion**: Sickle cells are rigid, leading to obstruction of small blood vessels, ischemia, and organ damage.
- **Hemolysis**: Sickled cells have a shorter lifespan (10-20 days vs. 120 days for normal RBCs), leading to chronic hemolytic anemia.
- **Chronic inflammation**: Recurrent vaso-occlusive events lead to endothelial damage, inflammation, and complications.

Clinical Features

- **Anemia**: Chronic hemolysis results in moderate to severe anemia.
- **Painful crises**: Vaso-occlusive crises cause severe pain, usually in bones, joints, and abdomen.
- **Splenic sequestration**: Acute pooling of RBCs in the spleen leads to severe anemia and hypovolemic shock, often in children.
- **Infections**: Functional asplenia increases susceptibility to infections, especially encapsulated organisms (e.g., Streptococcus pneumoniae).
- **Acute chest syndrome**: Vaso-occlusion in pulmonary vessels, presenting as chest pain, fever, hypoxia, and pulmonary infiltrates.
- **Stroke**: Increased risk due to cerebrovascular occlusion.
- **Avascular necrosis**: Especially in hips and shoulders.
- **Chronic complications**: Pulmonary hypertension, renal dysfunction, leg ulcers, and retinopathy.

Diagnosis

- **Hemoglobin electrophoresis**: Confirms HbS.
- **Peripheral blood smear**: Shows sickled RBCs, target cells, Howell-Jolly bodies (if asplenic).
- **CBC**: Normocytic or mildly macrocytic anemia with reticulocytosis.
- **Sickle solubility test**: Screening test for HbS presence.

Management

- **Hydroxyurea**: Increases fetal hemoglobin (HbF) production, reducing sickling.
- **Pain management**: NSAIDs, opioids during vaso-occlusive crises.
- **Infection prevention**: Vaccination (Pneumococcal, Meningococcal, H. influenzae) and prophylactic penicillin in children.
- **Blood transfusions**: For severe anemia, acute chest syndrome, stroke prevention.
- **Bone marrow transplant**: Curative in selected cases.
- **Gene therapy**: Emerging as a potential curative option.

Prognosis

- With appropriate treatment, patients may live into their 50s, but frequent complications and crises significantly affect quality of life.

Alpha Thalassemias

Definition

Alpha thalassemias are inherited blood disorders caused by reduced or absent synthesis of alpha-globin chains, leading to imbalanced hemoglobin production and microcytic hypochromic anemia.

Genetics

- Alpha-globin gene located on chromosome 16.
- Normally, there are four alpha-globin genes (αα/αα).
- Severity depends on the number of gene deletions/mutations.

Types

1. **Silent Carrier (1 gene deletion, αα/α-)**
   - Asymptomatic with no clinical significance.
   - Mild microcytosis.
2. **Alpha Thalassemia Trait (2 gene deletions, α-/α- or αα/--)**
   - Mild microcytic, hypochromic anemia.
   - Common in Southeast Asian, Mediterranean, and African populations.
3. **Hemoglobin H Disease (3 gene deletions, α-/--)**
   - Moderate to severe microcytic anemia.
   - Hemoglobin H (β4) forms due to excess beta chains.
   - Symptoms: Splenomegaly, fatigue, jaundice.
   - Risk of iron overload and complications.
4. **Hydrops Fetalis (4 gene deletions, --/--)**
   - Most severe form.
   - No production of alpha chains, leading to formation of Hemoglobin Bart's (γ4).
   - Severe fetal anemia, heart failure, hydrops fetalis, and usually results in death in utero or shortly after birth.

Clinical Features

- Vary based on severity (silent carrier to hydrops fetalis).
- Symptoms include pallor, fatigue, splenomegaly, jaundice, and growth retardation in severe cases.

Diagnosis

- Complete blood count (CBC): Microcytic, hypochromic anemia.
- Peripheral blood smear: Target cells, microcytes.
- Hemoglobin electrophoresis: Presence of abnormal hemoglobins (e.g., HbH, Hb Bart's).
- Genetic testing: To confirm the number of alpha-globin gene deletions.

Management

- Silent carrier and trait: No specific treatment.
- Hemoglobin H disease:
  - Folic acid supplementation.
  - Blood transfusions for severe anemia.
  - Monitoring for iron overload (iron chelation therapy if needed).
  - Splenectomy in selected cases.
- Hydrops fetalis: Prenatal diagnosis, genetic counseling, and intrauterine transfusions in selected cases.

Prognosis

- Silent carrier and alpha thalassemia trait: Good prognosis, normal life expectancy.
- Hemoglobin H disease: Variable, may require regular treatment.
- Hydrops fetalis: Fatal without intervention.

Beta Thalassemias

Definition

Beta Thalassemia refers to a group of inherited blood disorders characterized by reduced or absent synthesis of beta-globin chains of hemoglobin, leading to varying degrees of anemia.

Types

1. **Beta Thalassemia Minor (Trait)**
   - Heterozygous condition.
   - Usually asymptomatic or mild microcytic anemia.
   - Elevated HbA2 on electrophoresis.
2. **Beta Thalassemia Intermedia**
   - Milder form than Beta Thalassemia Major.
   - Moderate anemia, may require occasional blood transfusions.
   - Symptoms develop later in life.
3. **Beta Thalassemia Major (Cooley's Anemia)**
   - Homozygous condition.
   - Severe anemia requiring regular transfusions.
   - Symptoms: growth retardation, hepatosplenomegaly, skeletal deformities due to bone marrow expansion.

Pathophysiology

- **Mutation in HBB gene** on chromosome 11 results in reduced or absent beta-globin chain production.
- Imbalance between alpha and beta chains → free alpha chains precipitate → ineffective erythropoiesis and hemolysis.

Clinical Features

- **Beta Thalassemia Minor**: Mild anemia, usually asymptomatic, detected incidentally.
- **Beta Thalassemia Major**:
  - Severe anemia from infancy.
  - Hepatosplenomegaly.
  - Bone deformities (especially facial).
  - Growth failure and delayed puberty.
  - Iron overload due to frequent transfusions.

Diagnosis

- **CBC**: Microcytic hypochromic anemia.
- **Hemoglobin Electrophoresis**:
  - Increased HbA2 (>3.5%) in Beta Thalassemia Minor.
  - Elevated HbF in Beta Thalassemia Major and Intermedia.
- **Genetic Testing**: HBB gene mutations.

Complications

- **Iron Overload** (due to transfusions): Can lead to heart failure, liver cirrhosis, diabetes.
- **Skeletal Deformities**: Due to expanded bone marrow.
- **Cardiac complications**: Due to severe anemia or iron overload.

Management

- **Beta Thalassemia Minor**: No specific treatment required.
- **Beta Thalassemia Major**:
  - Regular blood transfusions to maintain Hb >9-10 g/dL.
  - **Iron Chelation Therapy**: To prevent iron overload (e.g., Deferoxamine, Deferasirox).
  - **Folic Acid Supplementation**: Helps erythropoiesis.
  - **Splenectomy**: Considered in cases of massive splenomegaly or high transfusion requirements.
  - **Hematopoietic Stem Cell Transplant (HSCT)**: Only curative treatment.

Prognosis

- **Beta Thalassemia Minor**: Excellent, normal life expectancy.
- **Beta Thalassemia Major**: Lifelong transfusions and chelation needed; HSCT can be curative but carries risks.

Prevention

- **Genetic Counseling**: For at-risk couples to prevent transmission.
- **Prenatal Diagnosis**: By chorionic villus sampling (CVS) or amniocentesis.

Aplastic Anemia

Definition

Aplastic anemia is a rare but serious condition characterized by pancytopenia due to bone marrow failure. It results in a significant reduction in the production of red blood cells, white blood cells, and platelets.

Etiology

- **Idiopathic (most common, ~70%)**
- **Secondary causes:**
  - **Drugs:** Chemotherapy, chloramphenicol, NSAIDs, anticonvulsants
  - **Toxins:** Benzene, radiation
  - **Infections:** Viral (hepatitis, EBV, HIV)
  - **Autoimmune disorders:** Lupus erythematosus
  - **Congenital:** Fanconi anemia

Pathophysiology

- Failure or destruction of hematopoietic stem cells leading to hypocellular bone marrow and pancytopenia.
- Possible immune-mediated attack on marrow or direct damage by external factors.

Clinical Features

- **Symptoms of anemia:** Fatigue, pallor, dyspnea
- **Leukopenia:** Recurrent infections
- **Thrombocytopenia:** Easy bruising, mucosal bleeding, petechiae
- **No splenomegaly** (important differentiator from other causes of pancytopenia)

Diagnosis

- **Complete Blood Count (CBC):** Pancytopenia (low RBCs, WBCs, platelets)
- **Reticulocyte count:** Low
- **Bone marrow biopsy:** Hypocellular marrow, replaced by fat
- **Exclusion of other causes of pancytopenia**

Differential Diagnosis

- Myelodysplastic syndromes
- Leukemia
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Megaloblastic anemia

Prognosis

- Variable, dependent on severity, age, and response to treatment.
- Better outcomes in younger patients with HSCT.

Treatment

- **Supportive care:**
  - Blood transfusions (RBCs, platelets)
  - Antibiotics for infections
- **Definitive treatments:**
  - **Immunosuppressive therapy:** Antithymocyte globulin (ATG), cyclosporine
  - **Hematopoietic stem cell transplantation (HSCT):** Curative option, especially for younger patients
  - **Growth factors:** G-CSF, GM-CSF may help in some cases
- **Avoidance of causative agents** (drugs, toxins)

Complications

- Infections
- Hemorrhage
- Risk of progression to leukemia or myelodysplastic syndrome (rare).

Anemia of Chronic Disease (ACD)

Definition

A form of anemia that occurs in the setting of chronic infection, inflammation, or malignancy, characterized by impaired iron utilization despite normal or increased iron stores.

Etiology

- Chronic inflammatory conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- Chronic infections (e.g., tuberculosis, HIV)
- Malignancies (e.g., lymphomas, carcinomas)
- Chronic kidney disease (CKD)

Pathophysiology

- Increased cytokine production (IL-6) leads to:
  - Increased hepcidin production by the liver, which blocks iron absorption from the gut and traps iron in macrophages, leading to reduced iron availability for erythropoiesis.
  - Suppressed erythropoietin production and bone marrow response.
  - Shortened red blood cell lifespan due to increased macrophage activity.

Clinical Features

- Fatigue, pallor, and symptoms of underlying chronic disease.
- Typically normocytic, normochromic anemia, though it may become microcytic in later stages.

Laboratory Findings

- **Hemoglobin**: Mild to moderate anemia (Hb 8-10 g/dL)
- **MCV**: Normal (normocytic) or low (microcytic)
- **Serum iron**: Low
- **Ferritin**: Normal or increased (reflecting adequate iron stores)
- **TIBC (Total Iron Binding Capacity)**: Low
- **Transferrin saturation**: Low
- **Erythropoietin**: Low or inappropriately normal

Diagnosis

- Diagnosis of exclusion, confirmed by the presence of chronic disease and characteristic lab findings.
- Rule out iron deficiency anemia by checking ferritin levels.

Treatment

- Treat the underlying chronic condition.
- Iron supplementation is usually ineffective unless there is concomitant iron deficiency.
- Erythropoiesis-stimulating agents (ESAs) can be considered in severe cases, especially in CKD.
- Blood transfusions in cases of severe anemia or symptomatic patients.

Prognosis

- Depends on the control of the underlying chronic disease.

Sickle Cell Disease

Definition

A genetic disorder characterized by the production of abnormal hemoglobin (hemoglobin S), leading to the formation of sickle-shaped red blood cells.

Pathophysiology

- **Mutation:** Caused by a single nucleotide mutation in the β-globin gene (GAG to GTG, glutamic acid to valine).
- **Hemoglobin S:** Causes red blood cells to become rigid, sticky, and shaped like crescents or sickles.
- **Deformity:** Leads to impaired blood flow and hemolysis, causing anemia and vaso-occlusive crises.

Clinical Features

- **Anemia:** Chronic hemolytic anemia due to the short lifespan of sickle cells.
- **Pain Crises:** Acute pain episodes due to vaso-occlusive events in small blood vessels.
- **Infections:** Increased susceptibility to infections due to spleen dysfunction.
- **Organ Damage:** Repeated vaso-occlusive episodes can lead to damage in organs like spleen, liver, kidneys, and lungs.
- **Delayed Growth:** Children may experience delayed physical growth and development.
- **Fatigue:** Chronic anemia leads to general fatigue and weakness.

Complications

- **Acute Chest Syndrome:** An acute pulmonary event often precipitated by infection or vaso-occlusive crises.
- **Stroke:** Increased risk due to cerebral vasculopathy.
- **Splenic Sequestration Crisis:** Sudden enlargement of the spleen leading to hypovolemic shock.
- **Priapism:** Painful, prolonged erections due to vaso-occlusive events in the penis.
- **Leg Ulcers:** Chronic leg ulcers can develop due to poor circulation.

Diagnosis

- **Hemoglobin Electrophoresis:** Confirms the presence of hemoglobin S.
- **Complete Blood Count (CBC):** Shows anemia and possibly sickle-shaped cells.
- **Peripheral Blood Smear:** Identifies sickle cells and other abnormalities.
- **Genetic Testing:** Confirms the diagnosis by detecting the sickle cell gene mutation.

Management

- **Pain Management:** Use of analgesics and hydration during pain crises.
- **Hydroxyurea:** Reduces sickling by increasing fetal hemoglobin (HbF) levels.
- **Blood Transfusions:** Used to reduce the number of sickle cells and manage severe anemia.
- **Bone Marrow Transplant:** Considered in severe cases; the only potential cure.
- **Vaccinations and Antibiotics:** Prevent infections due to spleen dysfunction.

Patient Education

- **Hydration:** Encourage adequate fluid intake to reduce sickling.
- **Avoid Triggers:** Educate on avoiding extreme temperatures and high altitudes.
- **Regular Monitoring:** Regular check-ups for early detection and management of complications.

Prognosis

Varies with severity and access to treatment. Improved with advances in management and early interventions.

Summary

Sickle Cell Disease is a genetic disorder causing abnormal hemoglobin production and resultant red blood cell deformation, leading to anemia, pain crises, and various complications. Early diagnosis, regular monitoring, and effective management strategies can significantly improve quality of life and outcomes for affected individuals.

Hemoglobin C Disease

Definition

A mild hemolytic anemia caused by the presence of Hemoglobin C (HbC), a variant of normal hemoglobin due to a point mutation in the β-globin gene, where glutamic acid is substituted by lysine at position 6.

Pathophysiology

- HbC polymerizes inside red blood cells (RBCs), leading to mild hemolysis and formation of target cells.
- Increased RBC rigidity results in premature destruction (extravascular hemolysis).

Genetics

- Autosomal recessive disorder.
- HbC arises from the β-globin gene (HBB) mutation (Glu6Lys).

Epidemiology

- Common in people of West African descent.
- Less severe than sickle cell disease.

Clinical Features

- Generally mild symptoms.
- **Hemolytic anemia**: Mild to moderate, chronic.
- **Splenomegaly**: Due to RBC destruction.
- Jaundice (rare).
- Gallstones due to chronic hemolysis.

Diagnosis

- **Hemoglobin electrophoresis**: Shows HbC as the predominant hemoglobin.
- **Peripheral blood smear**: Presence of target cells, microspherocytes, and occasional HbC crystals.
- Mild anemia (Hb typically 9-12 g/dL).

Complications

- Splenic sequestration (rare).
- Cholelithiasis (due to increased bilirubin from hemolysis).
- Retinopathy (in severe cases).

Management

- No specific treatment needed for asymptomatic individuals.
- Folic acid supplementation to support erythropoiesis.
- Treatment of complications such as gallstones and splenic enlargement.

Prognosis

- Generally favorable with a normal life expectancy.
- Complications are rare but can arise with severe hemolysis.

Hemoglobin E Disease

Definition

Hemoglobin E (HbE) disease is a common hemoglobin variant caused by a point mutation in the β-globin gene, resulting in substitution of glutamic acid by lysine at position 26 of the β-globin chain.

Genetics

- Autosomal recessive inheritance.
- The mutation leads to abnormal hemoglobin formation.

Epidemiology

- Prevalent in Southeast Asia, especially in Thailand, Cambodia, Laos, and parts of India.
- Common among individuals of Southeast Asian descent.

Pathophysiology

- HbE is mildly unstable and causes mild hemolysis.
- Homozygous (HbE/E): Mild anemia with microcytosis and hypochromia.
- Heterozygous (HbA/E): Usually asymptomatic.
- Compound heterozygous (HbE/β-thalassemia): More severe anemia and clinical manifestations.

Clinical Features

- **Homozygous HbE**:
  - Typically, asymptomatic or mild symptoms.
  - Mild microcytic anemia.
- **HbE/β-thalassemia**:
  - Varies from mild to severe anemia.
  - Splenomegaly.
  - Growth retardation and skeletal deformities in severe cases.

Diagnosis

- Complete blood count (CBC): Microcytic, hypochromic anemia.
- Hemoglobin electrophoresis or HPLC: Detects HbE.
- Genetic testing for β-globin mutations.

Prognosis

- Homozygous HbE: Good prognosis, usually no significant health impact.
- HbE/β-thalassemia: Prognosis depends on disease severity; severe forms require long-term management.

Management

- **Homozygous HbE**: No specific treatment needed, usually requires monitoring.
- **HbE/β-thalassemia**:
  - Regular transfusions in severe cases.
  - Iron chelation if iron overload occurs.
  - Folic acid supplementation.
  - Consideration for splenectomy in select cases.
  - Bone marrow transplantation in severe cases.

Polycythemia Vera (PV)

Definition

Polycythemia Vera (PV) is a myeloproliferative neoplasm characterized by increased red blood cell (RBC) mass, elevated hemoglobin/hematocrit levels, and often an increase in white blood cells and platelets.

Etiology

- **Primary**: Mutation in the JAK2 gene (most commonly JAK2 V617F) leading to constitutive activation of the erythropoietin receptor pathway.
- **Secondary**: Increased RBC production due to external factors such as chronic hypoxia, tumors producing erythropoietin, or other conditions leading to elevated erythropoietin levels.

Pathophysiology

- Clonal proliferation of hematopoietic stem cells in the bone marrow, resulting in increased production of RBCs, granulocytes, and platelets.
- Altered feedback regulation of erythropoiesis.

Clinical Features

- **Symptoms**: Headaches, dizziness, itching (especially after hot showers), fatigue, and blurred vision.
- **Signs**: Ruddy complexion, splenomegaly, and occasionally hepatomegaly. Symptoms related to thrombosis (e.g., deep vein thrombosis, pulmonary embolism) or bleeding may occur.

Laboratory Findings

- **Complete Blood Count (CBC)**: Elevated hemoglobin and hematocrit. Elevated white blood cells and platelets are common.
- **Bone Marrow Biopsy**: Hypercellularity with increased RBC, granulocyte, and platelet precursors.
- **Serum Erythropoietin**: Typically low, distinguishing PV from secondary causes of erythrocytosis.
- **JAK2 Mutation Testing**: Positive in approximately 95% of PV patients.

Diagnostic Criteria

Major Criteria:

- Elevated hemoglobin or hematocrit.
- Presence of JAK2 V617F or other functionally similar mutations.
- Bone marrow biopsy showing hypercellularity with increased erythroid, granulocytic, and megakaryocytic proliferation.
- Low serum erythropoietin level.

Minor Criteria:

- Evidence of endogenous erythroid colony formation in vitro.

Management

- **Phlebotomy**: Regular removal of blood to maintain hematocrit levels below 45% to reduce the risk of thrombosis.
- **Medications**:
  - **Hydroxyurea**: To reduce blood cell counts and decrease the risk of thrombosis.
  - **Aspirin**: Low-dose aspirin to reduce the risk of thrombosis.
  - **JAK2 Inhibitors**: Ruxolitinib for patients with inadequate response to other treatments or with symptoms resistant to conventional therapies.
- **Interferon-alpha**: In certain cases, particularly for younger patients or those who prefer a non-cytotoxic approach.

Complications

- **Thrombotic Events**: Increased risk of deep vein thrombosis, stroke, myocardial infarction.
- **Bleeding**: Due to platelet dysfunction.
- **Progression**: May evolve into myelofibrosis or acute myeloid leukemia (AML).

Follow-Up

- Regular monitoring of blood counts.
- Assessment for potential complications and secondary issues.

Prognosis

- Varies based on risk factors, treatment response, and presence of complications. With appropriate management, many patients have a normal life expectancy.

Hereditary Spherocytosis

Definition

Hereditary spherocytosis is a genetic hemolytic anemia characterized by the presence of spherocytes (spherical red blood cells) in the blood due to defects in the red cell membrane.

Clinical Features

- **Symptoms:** Fatigue, pallor, jaundice, and splenomegaly. Severe cases may present with hemolytic crisis.
- **Physical Exam:** Enlarged spleen (splenomegaly) is common.

Pathophysiology

- **Genetic Basis:** Autosomal dominant inheritance; mutations in genes encoding red cell membrane proteins, such as ankyrin, spectrin, or band 3.
- **Cellular Changes:** Defective membrane proteins lead to reduced membrane stability and loss of surface area, resulting in the formation of spherocytes.

Laboratory Findings

- **Complete Blood Count (CBC):** Anemia, elevated reticulocyte count.
- **Peripheral Blood Smear:** Presence of spherocytes (small, round, and hyperchromic red cells).
- **Osmotic Fragility Test:** Increased fragility of spherocytes in hypotonic solution.
- **Coombs Test:** Typically negative (to distinguish from autoimmune hemolytic anemia).

Diagnosis

- **Family History:** Often helpful in diagnosing hereditary spherocytosis.
- **Flow Cytometry:** Can detect the presence of spherocytes and membrane protein abnormalities.

Complications

- **Gallstones:** Due to increased bilirubin production from hemolysis.
- **Infections:** Increased risk post-splenectomy, particularly with encapsulated organisms.

Management

- **Supportive Care:** Folate supplementation and transfusions for severe anemia.
- **Splenectomy:** Often indicated for symptomatic relief and reduction of hemolysis. Generally recommended in children over 5 years old or adults if anemia is severe.

Prevention and Counseling

- Genetic counseling for families due to the hereditary nature of the condition.
- Vaccination against encapsulated organisms (e.g., pneumococcus) if splenectomy is performed.

Prognosis

- Generally good with appropriate management. Splenectomy improves symptoms but may increase the risk of infections and requires lifelong follow-up.

G6PD Deficiency

Definition

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder leading to reduced activity of the G6PD enzyme, crucial for protecting red blood cells from oxidative stress.

Epidemiology

- Prevalent in regions with high malaria incidence (e.g., Africa, Middle East, South Asia, Southeast Asia).
- Approximately 400 million people are affected globally.

Pathophysiology

- G6PD is an enzyme involved in the pentose phosphate pathway, producing NADPH, which protects red blood cells from oxidative damage.
- Deficiency impairs the red blood cells' ability to counteract oxidative stress, leading to hemolysis.

Genetics

- X-linked recessive inheritance.
- Most common in males; females can be carriers or affected if both X chromosomes are mutated.

Clinical Features

- **Acute Hemolytic Crisis:**
  - Triggered by infections, certain medications (e.g., sulfonamides, antimalarials), fava beans, or oxidative stress.
  - Symptoms include jaundice, pallor, dark urine, and fatigue.
- **Chronic Symptoms:**
  - Typically asymptomatic except during acute hemolytic episodes.

Diagnosis

Clinical History:

- Review of triggers for hemolysis (e.g., recent infections, medication use).

Laboratory Tests:

- Blood smear showing bite cells and Heinz bodies.
- Enzyme assays for G6PD activity (confirmatory test).
- Genetic testing (if needed for confirmation).

Management

Avoidance of Triggers:

- Avoid fava beans, certain medications, and manage infections promptly.

Supportive Care:

- Treatment of hemolytic episodes may require blood transfusions or supportive care.

Patient Education:

- Educate about avoiding known triggers and recognizing symptoms of hemolysis.

Prognosis

- Generally good with appropriate management and avoidance of triggers.
- Complications can arise if hemolysis is not managed effectively.

Prevention

- Genetic counseling for family planning.
- Screening for at-risk populations in endemic areas.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Definition

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired hematological disorder characterized by the destruction of red blood cells (hemolysis), leading to episodes of hemoglobinuria (hemoglobin in the urine), usually during the night.

Pathophysiology

- **Genetic Mutation:** PNH is caused by a somatic mutation in the PIGA gene, which results in the deficiency of glycosylphosphatidylinositol (GPI) anchor proteins on the surface of blood cells.
- **Complement Activation:** The absence of GPI-anchored proteins makes red blood cells susceptible to destruction by the complement system. This leads to chronic hemolysis.
- **Bone Marrow Dysfunction:** PNH often occurs in conjunction with bone marrow disorders like aplastic anemia or myelodysplastic syndromes.

Clinical Features

- **Hemolytic Anemia:** Symptoms include fatigue, pallor, shortness of breath, and jaundice.
- **Hemoglobinuria:** Dark-colored urine, particularly noticeable in the morning.
- **Abdominal Pain:** Due to thrombosis in abdominal veins.
- **Thrombosis:** Increased risk of venous thrombosis, especially in the hepatic, portal, and cerebral veins.

Diagnosis

- **Flow Cytometry:** Detects the absence of GPI-anchored proteins on red blood cells (e.g., CD55 and CD59).
- **Ham's Test:** A historic test for PNH (less commonly used now due to flow cytometry).
- **Sucrose Lysis Test:** Assesses red cell sensitivity to complement.

Management

- **Supportive Care:** Includes blood transfusions and iron supplementation.
- **Eculizumab:** A monoclonal antibody that inhibits complement activation, used to reduce hemolysis and related symptoms.
- **Bone Marrow Transplant:** Considered for severe cases or those with associated bone marrow disorders.
- **Anticoagulation:** To manage or prevent thrombosis.

Prognosis

- The disease course varies; some patients experience stable disease with appropriate treatment, while others may have progressive symptoms and complications.

Key Points

- PNH is a complex disorder with significant implications for blood cell destruction and thrombosis.
- Early diagnosis and treatment are crucial for managing symptoms and improving quality of life.

2 White Blood Cell Disorders

- Leukemias
  - Acute Lymphoblastic Leukemia (ALL)
  - Acute Myeloid Leukemia (AML)
  - Chronic Lymphocytic Leukemia (CLL)
  - Chronic Myeloid Leukemia (CML)
- Lymphomas
  - Hodgkin's Lymphoma
  - Non-Hodgkin's Lymphoma
- Plasma Cell Disorders
  - Multiple Myeloma
  - Waldenström's Macroglobulinemia
  - Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Other WBC Disorders
  - Neutropenia
  - Lymphocytosis
  - Eosinophilia
  - Myelodysplastic Syndromes (MDS)
  - Chronic Granulomatous Disease

Acute Lymphoblastic Leukemia (ALL)

Definition

Acute Lymphoblastic Leukemia (ALL) is a malignant disorder characterized by uncontrolled proliferation of immature lymphoid cells (lymphoblasts) in the bone marrow and peripheral blood.

Epidemiology

- Most common leukemia in children.
- Peak incidence: ages 2-5 years.
- Bimodal age distribution with a second peak in individuals >50 years.

Pathophysiology

- Originates from lymphoid progenitor cells, either B-cell or T-cell lineage.
- Abnormal clonal expansion of lymphoblasts interferes with normal hematopoiesis, leading to anemia, thrombocytopenia, and neutropenia.

Subtypes

- **B-ALL**: More common, derived from B-cell precursors.
- **T-ALL**: Less common, tends to present with mediastinal mass and higher white blood cell counts.

Clinical Features

- Symptoms due to bone marrow failure: fatigue, pallor (anemia), bleeding, bruising (thrombocytopenia), infections (neutropenia).
- Bone pain, especially in the long bones.
- Lymphadenopathy, hepatosplenomegaly.
- CNS involvement: headache, vomiting, cranial nerve palsies.
- Mediastinal mass (T-ALL).

Diagnosis

- **Complete Blood Count (CBC)**: Anemia, thrombocytopenia, variable WBC count.
- **Peripheral Blood Smear**: Presence of lymphoblasts.
- **Bone Marrow Aspiration/Biopsy**: Hypercellular marrow with >20% lymphoblasts.
- **Immunophenotyping (Flow Cytometry)**: To determine lineage (B-ALL vs. T-ALL).
- **Cytogenetics**: Important for prognosis (e.g., t(12;21), t(9;22) – Philadelphia chromosome).

Risk Stratification

- Based on age, WBC count, cytogenetics, and response to treatment.
- **High-risk features**: Age <1 or >10 years, WBC count >50,000, adverse cytogenetics (e.g., Philadelphia chromosome).

Prognosis

- Children: 85-90% cure rate.
- Adults: Worse prognosis with lower cure rates.
- Prognosis influenced by age, cytogenetic abnormalities, and initial response to therapy.

Treatment

- **Induction Chemotherapy**: To achieve remission.
- **Consolidation Therapy**: To eliminate residual disease.
- **Maintenance Therapy**: Long-term chemotherapy to prevent relapse (2-3 years).
- **CNS Prophylaxis**: Intrathecal chemotherapy (due to high risk of CNS involvement).
- **Targeted Therapy**: In Philadelphia chromosome-positive ALL (e.g., tyrosine kinase inhibitors like imatinib).
- **Stem Cell Transplant**: Considered in high-risk patients or in relapse.

Complications

- **Tumor Lysis Syndrome**: Metabolic derangements during treatment.
- **Infections**: Due to immunosuppression.
- **Relapse**: Can occur in the bone marrow, CNS, or testicles.

Acute Myeloid Leukemia (AML)

Definition

Acute Myeloid Leukemia (AML) is a clonal malignancy of hematopoietic stem cells, characterized by the proliferation of immature myeloid cells (myeloblasts) in the bone marrow and peripheral blood, leading to impaired normal hematopoiesis.

Epidemiology

- Most common acute leukemia in adults.
- Incidence increases with age (median age at diagnosis: ~65 years).

Etiology

- Genetic mutations (FLT3, NPM1, CEBPA).
- Previous chemotherapy/radiation (secondary AML).
- Environmental exposure (benzene, tobacco, ionizing radiation).
- Pre-existing hematologic disorders (myelodysplastic syndromes, myeloproliferative disorders).

Pathophysiology

- Proliferation of abnormal myeloblasts in the bone marrow.
- Blockage of differentiation of myeloid progenitor cells, leading to accumulation of blasts and suppression of normal hematopoiesis.
- Anemia, neutropenia, and thrombocytopenia due to marrow failure.

Clinical Features

- Fatigue, pallor (due to anemia).
- Fever, infections (due to neutropenia).
- Bleeding, bruising (due to thrombocytopenia).
- Bone pain, hepatosplenomegaly, lymphadenopathy (less common).
- Leukostasis (hyperleukocytosis): headache, visual disturbances, dyspnea (in high WBC count).

Laboratory Findings

- CBC: Anemia, thrombocytopenia, neutropenia.
- Peripheral blood smear: Circulating myeloblasts (>20% blasts in bone marrow/peripheral blood).
- Bone marrow biopsy: Hypercellular marrow with >20% myeloblasts.
- Cytogenetics: t(8;21), inv(16), t(15;17) (favorable), complex karyotype (unfavorable).
- Molecular mutations: FLT3-ITD, NPM1, CEBPA.

Classification

- WHO classification based on cytogenetics, molecular findings, and clinical features.
- Subtypes: AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML, etc.

Diagnosis

- Bone marrow aspiration and biopsy.
- Immunophenotyping by flow cytometry: CD13, CD33, CD34, CD117, MPO.
- Cytogenetic and molecular analysis (for prognosis and targeted therapy).

Prognosis

- Varies based on age, cytogenetics, molecular mutations, and response to treatment.
- Favorable: t(8;21), inv(16), NPM1 mutation without FLT3-ITD.
- Unfavorable: Complex karyotype, FLT3-ITD mutation.

Treatment

1. **Induction Therapy**:
   - "7+3" regimen: Cytarabine (7 days) + Anthracycline (3 days).
   - Goal: Complete remission (CR).
2. **Consolidation Therapy**:
   - High-dose cytarabine or allogeneic stem cell transplantation (for high-risk patients).
3. **Targeted Therapy**:
   - FLT3 inhibitors (midostaurin) for FLT3-mutated AML.
   - IDH inhibitors for IDH1/2-mutated AML.
4. **Supportive Care**:
   - Blood transfusions, antibiotics for infections, growth factors (G-CSF).

Complications

Infections, bleeding, leukostasis, tumor lysis syndrome, relapse.

Follow-Up

Regular monitoring of blood counts, bone marrow biopsies, and molecular markers for early detection of relapse.

Chronic Lymphocytic Leukemia (CLL)

Definition

A slow-growing leukemia characterized by the clonal proliferation of mature B-lymphocytes in the blood, bone marrow, and lymphoid tissues.

Epidemiology

- Most common adult leukemia in Western countries.
- Median age of diagnosis: 70 years.
- Male predominance (M:F= 2:1).

Pathophysiology

- Accumulation of functionally incompetent B-cells.
- Clonal expansion of CD5+ B cells.
- Mutations in *TP53*, *ATM*, *NOTCH1*, and *SF3B1* may play a role in progression.
- Impaired apoptosis due to overexpression of anti-apoptotic proteins like BCL2.

Clinical Features

- Often asymptomatic in early stages.
- Common findings: lymphadenopathy, hepatosplenomegaly, and fatigue.
- Advanced disease: infections (due to hypogammaglobulinemia), autoimmune hemolytic anemia, and thrombocytopenia.

Diagnosis

- Peripheral blood smear: small, mature lymphocytes with "smudge cells."
- Immunophenotyping: CD5+, CD19+, CD23+, CD20+ (dim).
- Bone marrow biopsy: lymphocytic infiltration.
- Flow cytometry: key diagnostic tool.
- Genetic studies: for prognostic information (e.g., *TP53* mutation).

Staging

Rai and Binet staging systems.

- **Rai:** based on lymphocytosis, lymphadenopathy, organomegaly, anemia, and thrombocytopenia.
- **Binet:** based on the number of involved areas and cytopenias.

Prognosis

- Highly variable depending on the presence of prognostic markers.
- Better prognosis: mutated IGHV, absence of *TP53* mutation, *13q* deletion.
- Poor prognosis: unmutated IGHV, *TP53* mutation, *17p* deletion.

Treatment

- Early stage (asymptomatic): watchful waiting.
- Indications for treatment: symptomatic disease, cytopenias, bulky disease, or rapid disease progression.
- First-line therapy: Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib).
- Other options: Venetoclax (BCL2 inhibitor), chemoimmunotherapy (e.g., FCR: fludarabine, cyclophosphamide, rituximab).
- Allogeneic stem cell transplant in selected cases.

Complications

- Infections (due to hypogammaglobulinemia and immune dysfunction).
- Transformation to aggressive lymphoma (Richter's transformation).
- Autoimmune hemolytic anemia or thrombocytopenia.

Follow-up

- Regular monitoring of blood counts, lymphadenopathy, and symptoms.
- Surveillance for transformation or secondary malignancies.

Chronic Myeloid Leukemia (CML)

Definition

- A myeloproliferative neoplasm characterized by the uncontrolled proliferation of mature and maturing myeloid cells, primarily affecting granulocytes (neutrophils, eosinophils, basophils).
- Driven by the **Philadelphia chromosome (t(9;22)** translocation) and **BCR-ABL1 fusion gene** leading to constitutive tyrosine kinase activation.

Epidemiology

- Accounts for ~15-20% of adult leukemias.
- Median age at diagnosis: ~50-60 years.
- Slight male predominance.

Phases

1. **Chronic Phase (CP):**
    - Majority diagnosed in this phase (~85%).
    - Indolent, asymptomatic, or mild symptoms.
2. **Accelerated Phase (AP):**
    - Disease progression with increasing blast count (10-19% blasts in blood or bone marrow).
3. **Blast Crisis (BC):**
    - Resembles acute leukemia (≥20% blasts).
    - Poor prognosis.

Clinical Features

- Fatigue, weight loss, night sweats.
- Splenomegaly (often massive), hepatomegaly.
- Anemia, thrombocytosis, or thrombocytopenia.
- Elevated white blood cell count (often >100,000/mm^3).

Diagnosis

- **Complete blood count (CBC):** Leukocytosis with left shift, basophilia, eosinophilia.
- **Bone marrow biopsy:** Hypercellular with granulocytic hyperplasia.
- **Cytogenetics:** Detection of the Philadelphia chromosome.
- **Molecular Testing:** BCR-ABL1 by PCR or FISH.

Treatment

- **Tyrosine Kinase Inhibitors (TKIs):** First-line treatment.
  - **Imatinib**, **Dasatinib**, **Nilotinib**.
  - Highly effective in chronic phase, inducing molecular remission.
- **Allogeneic stem cell transplantation**: Considered in TKI-resistant cases or advanced phases.
- **Monitoring:**
  - Quantitative PCR for BCR-ABL1 transcript levels.
  - Regular assessment of molecular response.

Prognosis

- Excellent long-term survival in chronic phase with TKI therapy (>90% 5-year survival).
- Poor prognosis in blast crisis.

Complications

- Transformation to acute leukemia (AML or ALL) in blast crisis.
- TKI resistance or intolerance.

Key Points

- Philadelphia chromosome and BCR-ABL1 fusion gene are hallmark features.
- TKIs have revolutionized CML management, turning it into a manageable chronic condition.
- Regular monitoring is crucial for assessing treatment response and detecting resistance.

Hodgkin's Lymphoma (HL)

Definition

A malignant lymphoma characterized by the presence of Reed-Sternberg cells.

Etiology

- Exact cause unknown but associated with Epstein-Barr Virus (EBV) in some cases.
- Risk factors: Family history, immunosuppression (e.g., HIV), history of infectious mononucleosis.

Subtypes

1. **Classical Hodgkin's Lymphoma (CHL):**
    - Nodular Sclerosis (most common)
    - Mixed Cellularity
    - Lymphocyte-rich
    - Lymphocyte-depleted
2. **Nodular Lymphocyte-Predominant Hodgkin's Lymphoma (NLPHL):** Less common, non-classical variant.

Clinical Features

- Painless lymphadenopathy (commonly cervical, mediastinal)
- "B symptoms": Fever, night sweats, weight loss (>10% in 6 months)
- Pruritus (itching), fatigue
- Alcohol-induced lymph node pain (rare but characteristic)

Diagnosis

- **Lymph Node Biopsy:** Presence of Reed-Sternberg cells (large, binucleate cells with “owl-eye” appearance).
- **Immunohistochemistry:** CD15+, CD30+ (for classical HL).
- **Staging Investigations:**
    - PET/CT scan: Assess extent of disease.
    - Bone marrow biopsy: For advanced stages.

Staging (Ann Arbor Staging)

Stage I: Involvement of a single lymph node region.

Stage II: Two or more lymph node regions on the same side of the diaphragm.

Stage III: Lymph nodes on both sides of the diaphragm.

Stage IV: Disseminated involvement (liver, bone marrow, etc.).

Treatment

- **Early-stage (I/II):**
  - ABVD chemotherapy (Adriamycin, Bleomycin, Vinblastine, Dacarbazine).
  - Involved-site radiation therapy (ISRT).
- **Advanced-stage (III/IV):**
  - ABVD or BEACOPP regimen (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone).
  - Stem cell transplantation for refractory or relapsed disease.
- **Targeted therapy:** Brentuximab vedotin (anti-CD30), PD-1 inhibitors for relapsed/refractory cases.

Prognosis

- Excellent overall survival with treatment, especially in early-stage disease.
- 5-year survival rate >90% in early-stage HL, but lower in advanced stages or relapsed cases.

Follow-up

- Regular monitoring with PET/CT scans.
- Long-term follow-up for treatment-related complications (e.g., secondary malignancies, cardiovascular disease).

Non-Hodgkin's Lymphoma (NHL)

Definition

A heterogeneous group of lymphoid malignancies originating from B-cells, T-cells, or NK cells, distinct from Hodgkin's lymphoma.

Epidemiology

- More common than Hodgkin's lymphoma.
- Incidence increases with age.
- Risk factors: Immunosuppression (HIV, transplant patients), autoimmune diseases, infections (e.g., EBV, HTLV-1, H. pylori), exposure to chemicals (e.g., pesticides).

Classification

- **B-cell NHL (85% of cases)**: e.g., Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma, Mantle cell lymphoma.
- **T-cell NHL (15%)**: e.g., Peripheral T-cell lymphoma, Anaplastic large cell lymphoma.

Clinical Features

- Painless lymphadenopathy (can be localized or generalized).
- B symptoms: Fever, night sweats, weight loss (>10%).
- Extranodal involvement: Gastrointestinal tract, skin, CNS, bone marrow.
- Symptoms depend on site of involvement (e.g., abdominal mass, skin lesions, CNS symptoms).

Diagnosis

- **Lymph node biopsy**: Gold standard for diagnosis.
- **Immunophenotyping**: Determines cell type (B or T cell).
- **Staging**: Ann Arbor staging system (I-IV).
- **Imaging**: CT, PET-CT for staging and assessment of extranodal involvement.
- **Bone marrow biopsy**: To assess marrow involvement.

Prognostic Factors

International Prognostic Index (IPI): Factors include age, performance status, stage, extranodal involvement, and LDH levels.

Management

- **Low-grade (indolent) NHL**: Observation in asymptomatic cases, rituximab-based therapy, radiotherapy for localized disease.
- **High-grade (aggressive) NHL**: Chemotherapy (e.g., CHOP - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone), often combined with Rituximab (anti-CD20 monoclonal antibody).
- **Relapsed/refractory disease**: High-dose chemotherapy followed by autologous stem cell transplant, CAR-T cell therapy for some subtypes.
- **CNS involvement**: Intrathecal chemotherapy.

Prognosis

- Varies by subtype, grade, and stage.
- Indolent lymphomas may have a long natural history but are not curable.
- Aggressive lymphomas can be curable with treatment but are rapidly progressive if untreated.

Complications

- Indolent lymphomas may have a long natural history but are not curable.
- Aggressive lymphomas can be curable with treatment but are rapidly progressive if untreated.
- Bone marrow failure
- Infections (due to immunosuppression),
- CNS involvement
- Secondary malignancies.

Multiple Myeloma

Definition

A malignant proliferation of plasma cells in the bone marrow, leading to excessive monoclonal immunoglobulin production (usually IgG or IgA).

Epidemiology

- More common in elderly patients (median age ~65-70 years)
- Slight male predominance
- Higher incidence in African American populations

Pathophysiology

- Clonal plasma cells produce a large amount of monoclonal protein (M-protein).
- Bone marrow infiltration by malignant plasma cells causes:
  - Bone destruction (osteolytic lesions)
  - Marrow failure (anemia, thrombocytopenia)
  - Immunosuppression (increased risk of infections)
- Renal impairment may occur due to light chain cast nephropathy (myeloma kidney).

CRAB Symptoms

- **C**: Hypercalcemia (due to bone resorption)
- **R**: Renal failure (Bence Jones proteinuria)
- **A**: Anemia (bone marrow infiltration)
- **B**: Bone pain and pathological fractures (lytic bone lesions)

Other symptoms: recurrent infections, fatigue, weight loss

Diagnosis

- **Blood tests**:
  - Monoclonal (M) protein in serum/urine (SPEP, UPEP)
  - Hypercalcemia, renal dysfunction, anemia
  - Increased serum β2-microglobulin (prognostic marker)
- **Bone marrow biopsy**: Clonal plasma cells ≥10%
- **Imaging**:
  - X-rays or MRI: lytic bone lesions
  - PET-CT: for detection of active lesions
- **Electrophoresis**: Monoclonal spike (M spike) on SPEP/UPEP
- **Free light chain assay**: Elevated kappa or lambda light chains

Differential Diagnosis

- Monoclonal gammopathy of undetermined significance (MGUS)
- Waldenström's macroglobulinemia
- Amyloidosis

Prognosis

- Highly variable; median survival 3-5 years with treatment
- Prognostic factors: serum β2-microglobulin, cytogenetic abnormalities (e.g., t(4;14), del(17p))

Treatment

- **Initial treatment**:
  - Immunomodulatory agents (thalidomide, lenalidomide)
  - Proteasome inhibitors (bortezomib)
  - Dexamethasone or other steroids
- **Supportive care**:
  - Bisphosphonates (to prevent bone disease)
  - Hydration and correction of hypercalcemia
- **Autologous stem cell transplantation**: in eligible patients
- **Relapsed/Refractory disease**:
  - Carfilzomib, pomalidomide, monoclonal antibodies (daratumumab)
- **Radiation therapy**: for localized bone pain or fractures

Waldenström's Macroglobulinemia (WM)

Definition

A rare, slow-growing B-cell lymphoma characterized by the overproduction of monoclonal IgM antibodies by lymphoplasmacytic cells in the bone marrow.

Etiology

Exact cause unknown; associated with **MYD88 L265P** mutation (found in >90% of cases).

Pathophysiology

Abnormal B cells proliferate and produce excess **IgM**, leading to hyperviscosity, infiltration of bone marrow, and organ involvement.

Clinical Features

- **Hyperviscosity syndrome** (due to high IgM levels): headaches, visual disturbances, dizziness, and bleeding.
- **Neuropathy**: due to cryoglobulins or amyloidosis.
- **Anemia**, fatigue, weight loss, night sweats.
- **Hepatosplenomegaly** and **lymphadenopathy**.
- Cold-induced **Raynaud's phenomenon** or acrocyanosis.
- May present with **cryoglobulinemia** and **amyloidosis**.

Diagnosis

- **Serum protein electrophoresis (SPEP)** and **immunofixation**: monoclonal IgM spike.
- **Bone marrow biopsy**: lymphoplasmacytic infiltration.
- **Peripheral blood smear**: rouleaux formation.
- **MYD88 mutation analysis**.
- Increased **serum viscosity** in symptomatic patients.

Differential Diagnosis

- Multiple myeloma.
- Chronic lymphocytic leukemia (CLL).
- Other IgM-secreting conditions (e.g., IgM myeloma).

Complications

- **Hyperviscosity syndrome** (requires urgent plasmapheresis).
- **Cryoglobulinemia**.
- **Amyloidosis**.
- Secondary malignancies.

Management

- **Asymptomatic patients**: Observation.
- **Symptomatic patients**: Combination of chemotherapy and monoclonal antibodies.
    - **Rituximab-based therapy** (with or without chemotherapy).
    - **Plasmapheresis**: for acute hyperviscosity symptoms.
    - **Bruton's tyrosine kinase inhibitors** (e.g., Ibrutinib).
    - **Stem cell transplant** in younger or fit patients.

Prognosis

Slow progression, median survival ~5-10 years depending on disease burden and response to treatment.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Definition

A premalignant condition characterized by the presence of a monoclonal protein (M-protein) in the blood without evidence of malignant plasma cell disorder or end-organ damage.

Epidemiology

- Common in individuals over 50 years of age.
- Incidence increases with age; around 3% of individuals over 50 and 5% over 70 have MGUS.
- Slight male predominance.

Pathophysiology

- Monoclonal proliferation of plasma cells, producing a single type of immunoglobulin (IgG, IgA, or IgM).
- The condition may evolve into multiple myeloma, Waldenström's macroglobulinemia, or amyloidosis.

Types

- **Non-IgM MGUS**: Most common; precursor to multiple myeloma.
- **IgM MGUS**: Precursor to Waldenström's macroglobulinemia.
- **Light chain MGUS**: Precursor to light chain multiple myeloma or AL amyloidosis.

Diagnostic Criteria

(International Myeloma Working Group):

- Serum monoclonal protein (M-protein) < 3 g/dL.
- Clonal bone marrow plasma cells < 10%.
- No evidence of CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions).

Clinical Features

- Asymptomatic.
- Detected incidentally during evaluation for other conditions (e.g., routine blood tests).

Key Investigations

- Serum protein electrophoresis (SPEP) and immunofixation.
- Serum free light chain assay.
- Bone marrow biopsy (if needed to exclude other plasma cell disorders).

Risk of Progression

- Approximately 1% per year risk of progression to multiple myeloma or related disorders.
- Higher risk with elevated serum M-protein levels, abnormal free light chain ratio, and non-IgG MGUS.

Management

- No specific treatment for MGUS.
- Regular monitoring (every 6-12 months) to detect progression.
- Assess for signs of end-organ damage (CRAB criteria).

Prognosis

- Most patients remain stable without progression.
- Requires lifelong monitoring due to the risk of transformation into malignancy.

Neutropenia

Definition

- Neutropenia is defined as an abnormally low concentration of neutrophils (<1500 cells/μL in adults).
- Classified as:
  - Mild: 1000-1500 cells/μL
  - Moderate: 500-1000 cells/μL
  - Severe: <500 cells/μL (agranulocytosis)

Etiology

Congenital:

- Severe congenital neutropenia (Kostmann syndrome)
- Cyclic neutropenia

Acquired:

- **Infections:** Viral (HIV, hepatitis, EBV), bacterial sepsis
- **Drug-induced:** Chemotherapy, antibiotics (e.g., sulfonamides), antipsychotics (e.g., clozapine)
- **Bone marrow disorders:** Aplastic anemia, leukemias, myelodysplastic syndromes
- **Autoimmune:** Systemic lupus erythematosus (SLE), Felty's syndrome
- **Nutritional deficiencies:** Vitamin B12, folate

Clinical Features

- Asymptomatic in mild cases
- Infections due to compromised immunity:
  - **Skin:** Abscesses, cellulitis
  - **Oral cavity:** Ulcers, gingivitis
  - **Respiratory tract:** Pneumonia
  - **Fever of unknown origin (FUO)** in severe neutropenia

Diagnosis

- **Complete blood count (CBC)** with differential
- **Bone marrow biopsy** if marrow pathology is suspected
- **Peripheral blood smear** to assess morphology
- **Infection screening:** Blood cultures, viral panels
- **Autoimmune and genetic tests** if indicated

Treatment

- **Treat underlying cause:** Infection, drug discontinuation, nutritional correction
- **Granulocyte colony-stimulating factor (G-CSF):** For severe cases, especially in chemotherapy-induced neutropenia
- **Antibiotic prophylaxis:** In high-risk patients to prevent infections
- **Hematopoietic stem cell transplant (HSCT):** For severe congenital cases or bone marrow failure

Complications

- Severe bacterial and fungal infections (febrile neutropenia)
- Sepsis
- Risk of mortality increases with severity of neutropenia and presence of infections

Prognosis

- Depends on underlying cause and promptness of treatment
- Congenital neutropenia may require lifelong management

Lymphocytosis

Definition

Lymphocytosis refers to an elevated level of lymphocytes in the blood, typically defined as more than 4,000 lymphocytes per microliter (μL) of blood in adults, and higher thresholds in children. It is a common hematologic finding and can be indicative of various underlying conditions.

Causes

1. **Infections:**
   - **Viral Infections:** Common causes include Epstein-Barr virus (EBV) infection (mononucleosis), cytomegalovirus (CMV), and HIV.
   - **Bacterial Infections:** Pertussis and tuberculosis may also cause lymphocytosis.
2. **Chronic Lymphoproliferative Disorders:**
   - **Chronic Lymphocytic Leukemia (CLL):** Characterized by an increase in mature lymphocytes.
   - **Lymphocytic Leukemia:** Other types may present with elevated lymphocyte counts.
3. **Autoimmune Diseases:**
   - **Rheumatoid Arthritis:** May present with secondary lymphocytosis.
   - **Systemic Lupus Erythematosus (SLE):** Can also be associated with elevated lymphocyte counts.
4. **Stress Reactions:**
   - **Acute Stress:** Conditions like trauma or severe illness can temporarily elevate lymphocyte levels.
5. **Other Conditions:**
   - **Hypersensitivity Reactions:** Allergies and some drug reactions may lead to lymphocytosis.
   - **Smoking:** Chronic smoking has been associated with elevated lymphocyte counts.

Clinical Features

Symptoms of Underlying Condition: The clinical presentation is usually related to the cause of lymphocytosis rather than the lymphocytosis itself. Symptoms might include fever, weight loss, night sweats, or symptoms related to specific infections or diseases.

Diagnosis

- **Complete Blood Count (CBC):** Confirmatory test showing elevated lymphocyte counts.
- **Peripheral Blood Smear:** To differentiate between types of lymphocytes and identify atypical lymphocytes.
- **Bone Marrow Biopsy:** May be indicated in chronic or unexplained lymphocytosis to evaluate for lymphoproliferative disorders.
- **Flow Cytometry:** Used to characterize lymphocyte subsets in cases of suspected leukemia or lymphoma.

Management

- **Treat Underlying Cause:** Address the primary condition causing lymphocytosis. Treatment may include antiviral medications for infections, immunosuppressive drugs for autoimmune diseases, or chemotherapy for malignancies.
- **Follow-up:** Regular monitoring may be required to assess response to treatment and progression of the underlying condition.

Prognosis

Varies with Cause: The outcome depends on the underlying condition causing lymphocytosis. For infections, prognosis is generally good with appropriate treatment. For lymphoproliferative disorders, prognosis varies and depends on disease stage and response to therapy.

Key Points

- Lymphocytosis is a common finding with a broad differential diagnosis.
- Accurate diagnosis often requires correlating lymphocyte count with clinical features and additional diagnostic tests.
- Management focuses on treating the underlying cause rather than the lymphocytosis itself.

Eosinophilia

Definition

Eosinophilia is an elevated level of eosinophils in the blood, defined as an eosinophil count greater than 500 cells/μL. Eosinophils are a type of white blood cell involved in allergic reactions and combating parasitic infections.

Classification

1. **Primary Eosinophilia:**
    - **Myeloproliferative Disorders:** Conditions such as chronic eosinophilic leukemia.
    - **Hypereosinophilic Syndrome (HES):** A rare disorder characterized by persistent eosinophilia with organ damage.
2. **Secondary Eosinophilia:**
    - **Allergic Disorders:** Includes asthma, allergic rhinitis, and eczema.
    - **Parasitic Infections:** Particularly helminth infections such as Strongyloides or Schistosomiasis.
    - **Autoimmune Diseases:** Systemic lupus erythematosus, rheumatoid arthritis.
    - **Drug Reactions:** Reactions to medications like antibiotics or nonsteroidal anti-inflammatory drugs (NSAIDs).
    - **Neoplasms:** Certain cancers, such as lymphomas or solid tumors.

Clinical Presentation

- **Symptoms:** Vary depending on the underlying cause; can include fever, rash, cough, dyspnea, abdominal pain, or weight loss.
- **Organ-Specific Manifestations:** May involve skin (e.g., rash), respiratory (e.g., asthma), gastrointestinal (e.g., eosinophilic esophagitis), or cardiovascular systems (e.g., eosinophilic myocarditis).

Diagnosis

- **Clinical History and Physical Examination:** Identifying potential causes such as allergies or recent travel history.
- **Laboratory Tests:**
  - **Complete Blood Count (CBC):** To confirm eosinophilia and assess other blood parameters.
  - **Peripheral Blood Smear:** To evaluate eosinophil morphology.
  - **Bone Marrow Biopsy:** If a primary myeloproliferative disorder is suspected.
  - **Serological Tests:** To identify underlying infections or autoimmune conditions.

Management

Treat Underlying Cause: Essential for effective management; may include:

- **Antihistamines and Corticosteroids:** For allergic conditions.
- **Antiparasitic Medications:** For parasitic infections.
- **Specific Therapies:** For autoimmune diseases or malignancies.

Supportive Care: To manage symptoms and complications.

Prognosis

Depends on the underlying cause and response to treatment. Chronic or severe eosinophilia associated with significant organ damage may have a more guarded prognosis.

Key Points

- Always investigate the underlying etiology of eosinophilia.
- Management should be tailored to the specific cause and associated symptoms.
- Regular monitoring and follow-up may be required for chronic or severe cases.

Myelodysplastic Syndromes (MDS)

Definition

Myelodysplastic Syndromes (MDS) are a group of heterogeneous bone marrow disorders characterized by ineffective hematopoiesis, leading to dysplastic changes in hematopoietic cells and resulting in cytopenias.

Etiology

- **Primary (De novo)**: Occurs without a prior identifiable cause.
- **Secondary**: Associated with previous exposure to:
  - **Chemotherapy**: Often after treatment for other cancers.
  - **Radiation**: History of radiotherapy.
  - **Toxins**: Benzene, heavy metals.

Pathophysiology

- Ineffective hematopoiesis due to abnormal differentiation and maturation of hematopoietic stem cells.
- Results in peripheral cytopenias despite normal or increased numbers of hematopoietic cells in the bone marrow.

Classification

- **French-American-British (FAB) Classification**:
  - Refractory Anemia (RA)
  - Refractory Anemia with Ringed Sideroblasts (RARS)
  - Refractory Cytopenia with Excess Blasts (RCiEB)
  - Refractory Anemia with Excess Blasts (RAEB)
  - Chronic Myelomonocytic Leukemia (CMML)
- **World Health Organization (WHO) Classification**:
  - MDS with Single-Lineage Dysplasia
  - MDS with Multilineage Dysplasia
  - MDS with Ringed Sideroblasts
  - MDS with Excess Blasts
  - MDS/MPN (Myelodysplastic/Myeloproliferative Neoplasms)
  - MDS Associated with Isolated Del(5q)

Clinical Features

- **Anemia**: Fatigue, pallor.
- **Neutropenia**: Increased susceptibility to infections.
- **Thrombocytopenia**: Bleeding or bruising.

Diagnosis

- **Bone Marrow Biopsy**: Shows dysplastic changes in hematopoietic cells.
- **Peripheral Blood Smear**: Identification of dysplastic cells.
- **Cytogenetics**: Identification of chromosomal abnormalities (e.g., del(5q), del(7q)).
- **Flow Cytometry**: To assess lineage and immunophenotyping.

Prognosis

- **Low Risk**: Usually managed with supportive care and erythropoiesis-stimulating agents.
- **Intermediate/High Risk**: May require more intensive treatment, such as hypomethylating agents (e.g., azacitidine, decitabine) or allogeneic stem cell transplantation.

Treatment

- **Supportive Care**: Blood transfusions, antibiotics, growth factors.
- **Disease-Modifying Therapy**: Hypomethylating agents (azacitidine, decitabine).
- **Allogeneic Stem Cell Transplantation**: Considered for eligible patients with high-risk MDS.
- **Experimental Therapies**: Ongoing clinical trials for novel treatments.

Complications

- **Progression to Acute Myeloid Leukemia (AML)**: Approximately 30% of MDS patients may transform into AML.
- **Infection**: Due to neutropenia.
- **Bleeding**: Due to thrombocytopenia.

Follow-Up

- Regular monitoring of blood counts and bone marrow status.
- Surveillance for transformation to acute leukemia.

Chronic Granulomatous Disease (CGD)

Definition

Chronic Granulomatous Disease (CGD) is a rare, genetic disorder characterized by the inability of phagocytes (such as neutrophils and macrophages) to kill certain types of bacteria and fungi. This leads to recurrent, severe infections and the formation of granulomas, which are clusters of immune cells that form in response to the persistent infection.

Etiology

Genetic Inheritance:

- Most commonly X-linked recessive (X-linked CGD) affecting males.
- Autosomal recessive forms (such as CYBB mutations) are also present.

Pathophysiology

- Deficiency or dysfunction of the NADPH oxidase enzyme complex.
- The NADPH oxidase complex is essential for generating reactive oxygen species (ROS), which are crucial for the killing of pathogens by phagocytes.
- Impaired ROS production leads to the inability to effectively eliminate certain bacteria and fungi, resulting in chronic infections and inflammation.

Clinical Features

- Recurrent bacterial and fungal infections.
  - Common pathogens include **Staphylococcus aureus**, **Aspergillus species**, and **Candida species**.
- Chronic granulomas in various organs (lungs, liver, lymph nodes).
- Symptoms can include chronic pneumonia, lymphadenopathy, skin infections, and gastrointestinal issues.

Diagnosis

- **NADPH Oxidase Activity Test:** Measurement of oxidative burst in neutrophils. Deficient activity indicates CGD.
- **Genetic Testing:** Identification of mutations in genes encoding NADPH oxidase components (e.g., CYBB, CYBA, NCF1, NCF2, NCF4).
- **Dihydrorhodamine 123 (DHR) Test:** Flow cytometry-based test assessing the production of ROS by neutrophils.

Management

- **Antibiotic Prophylaxis:** Continuous prophylactic antibiotics and antifungal medications to prevent infections.
- **Interferon-gamma Therapy:** Can reduce the frequency and severity of infections.
- **Bone Marrow Transplant:** The only potential curative treatment; may be considered for severe cases.
- **Supportive Care:** Regular monitoring and prompt treatment of infections, management of granulomas, and overall supportive care.

Complications

- Chronic infections leading to organ damage.
- Formation of granulomas in various tissues can cause complications like obstruction or compression of organs.

Prognosis

- Varies based on severity, timeliness of diagnosis, and response to treatment.
- Advances in treatment have improved the outlook for many patients, especially with early diagnosis and appropriate management.

Key Points

- CGD is a serious condition requiring lifelong management and monitoring.
- Early diagnosis and intervention are crucial to prevent severe infections and complications.
- Genetic counseling may be recommended for affected families.

3 Platelet Disorders

- Thrombocytopenia
  - Immune Thrombocytopenic Purpura (ITP)
  - Thrombotic Thrombocytopenic Purpura (TTP)
  - Heparin-Induced Thrombocytopenia (HIT)
  - Disseminated Intravascular Coagulation (DIC)
- Thrombocytosis
  - Essential Thrombocythemia
- Qualitative Platelet Disorders
  - Bernard-Soulier Syndrome
  - Glanzmann's Thrombasthenia

Immune Thrombocytopenic Purpura (ITP)

Definition

ITP is an autoimmune disorder characterized by a low platelet count (thrombocytopenia) leading to increased bleeding risk and easy bruising.

Types

- **Primary ITP**: No associated condition; autoimmune in nature.
- **Secondary ITP**: Associated with other diseases (e.g., systemic lupus erythematosus, HIV, or hepatitis).

Etiology

- **Autoimmune Destruction**: Antibodies target and destroy platelets, often by splenic macrophages.
- **Pathophysiology**: Autoantibodies bind to platelet surface antigens, leading to platelet destruction.

Clinical Features

Symptoms:

- **Bleeding**: Easy bruising, petechiae, mucosal bleeding (gums, nosebleeds).
- **Purpura**: Purple spots on the skin.
- **Fatigue**: Due to chronic bleeding or anemia.

Signs:

- **Normal Bone Marrow**: Usually found in bone marrow aspiration/biopsy.
- **Normal Coagulation Profile**: PT and aPTT are typically normal.

Diagnosis

Laboratory Tests:

- **Platelet Count**: Low.
- **Bone Marrow Examination**: Normal or increased megakaryocytes.
- **Peripheral Blood Smear**: May show large platelets.
- **Exclusion**: Rule out other causes of thrombocytopenia (e.g., leukemia,

Management

First-line Treatment:

- **Observation**: For mild cases without bleeding.
- **Medications**:
  - **Corticosteroids**: First-line for symptomatic relief.
  - **IVIG**: For rapid response, especially in severe cases.
  - **Anti-D Immunoglobulin**: For patients with Rh-positive blood and no evidence of hemolysis.

Second-line Treatments:

- **Thrombopoietin Receptor Agonists**: (e.g., eltrombopag, romiplostim) to stimulate platelet production.
- **Immunosuppressive Agents**: (e.g., azathioprine, mycophenolate mofetil) in refractory cases.

Surgical Treatment:

- **Splenectomy**: Considered if medical treatments fail, as the spleen is the primary site of platelet destruction.

Prognosis

Variable: Some patients achieve long-term remission, while others may have a chronic course. The overall prognosis depends on the response to treatment and the presence of any secondary causes.

Follow-up

- **Regular Monitoring**: Platelet counts, assessment of bleeding symptoms, and response to therapy.
- **Patient Education**: Importance of avoiding activities that increase bleeding risk.

Complications

- **Bleeding**: Severe cases may lead to life-threatening hemorrhage.
- **Infection**: Post-splenectomy patients are at higher risk of infections.

Thrombotic Thrombocytopenic Purpura (TTP)

Definition

Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening blood disorder characterized by the formation of small blood clots throughout the small blood vessels, leading to a reduction in platelet count (thrombocytopenia) and organ damage.

Etiology

- **Primary TTP**: Often caused by a deficiency of the enzyme ADAMTS13, which is responsible for cleaving von Willebrand factor (vWF). This deficiency can be congenital or acquired (autoimmune).
- **Secondary TTP**: Can be associated with various conditions, including autoimmune diseases, pregnancy, infections, drugs, and malignancies.

Pathophysiology

- **ADAMTS13 Deficiency**: Leads to accumulation of large von Willebrand factor multimers, which promote excessive platelet aggregation and microvascular thrombi formation.
- **Microangiopathic Hemolytic Anemia**: Results from the fragmentation of red blood cells as they pass through obstructed vessels.

Clinical Features

1. **Microangiopathic Hemolytic Anemia**: Symptoms include fatigue, pallor, and jaundice. Laboratory findings include elevated lactate dehydrogenase (LDH) and low haptoglobin levels.
2. **Thrombocytopenia**: Low platelet count, leading to bleeding symptoms such as petechiae, purpura, and mucosal bleeding.
3. **Neurological Symptoms**: Headaches, seizures, altered mental status, or stroke-like symptoms.
4. **Renal Dysfunction**: Acute kidney injury or chronic renal impairment.
5. **Fever**: Less common but may be present in some cases.

Diagnosis

- **Laboratory Tests**:
  - Complete blood count (CBC): Low platelet count.
  - Peripheral blood smear: Presence of schistocytes (fragmented red cells).
  - Serum LDH: Elevated.
  - Haptoglobin: Decreased.
  - ADAMTS13 activity and inhibitor levels: Low enzyme activity with the presence of inhibitors confirm the diagnosis.
- **Clinical Criteria**: Based on the pentad of symptoms: microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, renal symptoms, and fever.

Treatment

- **Plasma Exchange (Plasmapheresis)**: Primary treatment to remove inhibitory antibodies and replace deficient ADAMTS13.
- **Corticosteroids**: To reduce inflammation and immune response.
- **Rituximab**: For patients with severe or refractory disease, especially when there is an autoimmune component.
- **Supportive Care**: Includes managing symptoms, treating organ dysfunction, and transfusions if necessary.
- **Avoidance of Platelet Transfusions**: Platelet transfusions can worsen the condition by promoting more thrombi formation.

Prognosis

- **With Treatment**: Early and aggressive treatment improves outcomes; however, relapses are possible.
- **Without Treatment**: High mortality rate due to complications like organ failure and severe bleeding.

Follow-Up

- Regular monitoring of platelet counts, renal function, and neurological status.
- Long-term follow-up for potential relapse or long-term complications.

Key Points

- TTP is a medical emergency requiring prompt diagnosis and treatment.
- Plasma exchange is the cornerstone of therapy and should be initiated as soon as possible.
- The condition has a variable prognosis, with timely intervention significantly improving survival rates.

Heparin-Induced Thrombocytopenia (HIT)

Definition

Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated adverse reaction to heparin characterized by a significant drop in platelet count and an increased risk of thrombosis.

Types

HIT Type 1:

- **Onset:** Within 1-2 days of heparin therapy.
- **Pathophysiology:** Non-immune, caused by direct platelet aggregation.
- **Platelet Count:** Mild drop, usually >100,000/µL.
- **Prognosis:** Generally benign, platelet count recovers despite continued heparin.

HIT Type 2:

- **Onset:** 5-14 days after heparin exposure (can be sooner if recent heparin exposure).
- **Pathophysiology:** Immune-mediated, caused by antibodies against the heparin-platelet factor 4 (PF4) complex.
- **Platelet Count:** Severe drop (<100,000/µL), can be <50,000/µL.
- **Risk:** High risk of thrombosis (venous and arterial).

Diagnosis

1. **Clinical Criteria:**
   - **4Ts Score:** Thrombocytopenia, Timing, Thrombosis, and Other causes.
   - **High Probability:** Score of ≥6.
2. **Laboratory Tests:**
   - **Antibody Tests:** Enzyme-linked immunosorbent assay (ELISA) for PF4/heparin antibodies.
   - **Functional Assays:** Serotonin release assay or heparin-induced platelet aggregation test (more specific).

Management

Immediate Actions:

- **Discontinue Heparin:** Both unfractionated heparin and low molecular weight heparin.
- **Alternative Anticoagulation:** Start with non-heparin anticoagulants such as direct thrombin inhibitors (e.g., argatroban, bivalirudin) or fondaparinux.

Anticoagulation Monitoring:

- **Monitoring:** Regularly monitor platelet counts and adjust anticoagulation therapy as needed.
- **Avoid:** Vitamin K antagonists (e.g., warfarin) until platelet count recovers to prevent skin necrosis.

Complications

- **Thrombosis:** Risk of both venous (e.g., deep vein thrombosis, pulmonary embolism) and arterial thrombosis (e.g., myocardial infarction, stroke).
- **Mortality:** Increased risk if not managed properly.

Prevention

- **Risk Assessment:** Use alternative anticoagulants in patients with a history of HIT.
- **Monitoring:** Regular platelet counts in patients receiving heparin.

Prognosis

- **Recovery:** Platelet counts usually normalize within 4-6 weeks with appropriate management.

Disseminated Intravascular Coagulation (DIC)

Definition

Disseminated Intravascular Coagulation (DIC) is a serious, potentially life-threatening disorder characterized by systemic activation of the coagulation cascade, leading to the formation of small blood clots throughout the blood vessels, which depletes clotting factors and platelets, resulting in bleeding.

Etiology

1. **Infections:** Sepsis, especially Gram-negative bacterial infections.
2. **Obstetric Complications:** Eclampsia, abruptio placentae, and amniotic fluid embolism.
3. **Trauma:** Severe injuries or burns.
4. **Malignancies:** Acute promyelocytic leukemia (APL), solid tumors.
5. **Severe Hypoxia:** Associated with respiratory distress syndrome.
6. **Tissue Damage:** Major surgeries or necrotic tissue.

Pathophysiology

- **Activation of Coagulation:** Triggered by pro-coagulant substances (e.g., tissue factor) released into the bloodstream.
- **Microvascular Thrombosis:** Formation of small clots in the microcirculation leading to organ damage and ischemia.
- **Consumption Coagulopathy:** Depletion of clotting factors and platelets, leading to bleeding.
- **Fibrinolysis:** Excessive breakdown of fibrin, contributing to bleeding tendencies.

Clinical Features

- **Bleeding:** Manifestations include petechiae, purpura, bleeding gums, gastrointestinal bleeding, and hematuria.
- **Thrombosis:** May present as organ dysfunction, such as renal failure, hepatic dysfunction, or respiratory distress.
- **Skin Changes:** Gangrene or necrosis in severe cases.
- **Shock:** Due to severe bleeding and multi-organ dysfunction.

Diagnosis

Laboratory Tests:

- **Coagulation Profile:** Prolonged PT (Prothrombin Time) and aPTT (Activated Partial Thromboplastin Time).
- **Platelets:** Decreased platelet count.
- **Fibrinogen:** Decreased fibrinogen levels.
- **D-dimer:** Elevated D-dimer levels indicating increased fibrinolysis.
- **Peripheral Blood Smear:** May show microangiopathic hemolytic anemia.

Management

- **Address Underlying Cause:** Treatment of the underlying condition (e.g., antibiotics for sepsis, obstetric intervention).
- **Supportive Care:**
  - **Fluid Resuscitation:** To manage shock and maintain blood pressure.
  - **Transfusion Therapy:** Platelets, fresh frozen plasma (FFP), and cryoprecipitate as needed.
- **Anticoagulants:** Controversial; used selectively depending on the situation and risk of bleeding.
- **Monitoring:** Close monitoring of coagulation parameters and organ function.

Prognosis

Variable: Depends on the underlying cause, timeliness of treatment, and severity of organ involvement. Early recognition and management improve outcomes.

Essential Thrombocythemia (ET)

Definition

Essential Thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an elevated platelet count due to the overproduction of platelets by megakaryocytes in the bone marrow.

Etiology

- **Primary ET**: Often associated with somatic mutations in genes such as JAK2 (V617F), CALR, or MPL.
- **Secondary ET**: Can occur in response to other conditions such as chronic inflammation, infection, or iron deficiency.

Clinical Features

- **Symptoms**: May be asymptomatic or present with symptoms due to thrombotic or bleeding complications. Common symptoms include headaches, dizziness, and visual disturbances.

Diagnosis

- **Blood Tests**: Elevated platelet count (often >450,000/μL), normal or slightly increased hemoglobin and white blood cell count.
- **Bone Marrow Biopsy**: Increased number of megakaryocytes with normal maturation.
- **Genetic Testing**: Detection of JAK2, CALR, or MPL mutations can confirm diagnosis.
- **Other Tests**: Exclusion of secondary causes of thrombocytosis.

Treatment

- **Low-Risk Patients**: Often monitored without immediate treatment; may use low-dose aspirin to reduce thrombotic risk.
- **High-Risk Patients**: Treatment with cytoreductive therapy to lower platelet counts, such as hydroxyurea, interferon-alpha, or anagrelide.
- **Management of Symptoms**: Address complications such as thrombosis or bleeding as needed.

Complications

Thrombotic events (e.g., stroke, myocardial infarction), bleeding complications (e.g., gastrointestinal bleeding, easy bruising), and transformation to myelofibrosis or acute leukemia.

Prognosis

- **Overall**: Generally good, especially with appropriate management; however, the risk of progression to more severe myeloproliferative disorders or acute leukemia exists.
- **Long-Term**: Regular follow-up required to monitor for complications and disease progression.

Key Points

- **Early Detection**: Crucial for effective management and prevention of complications.
- **Multidisciplinary Approach**: Often involves hematologists, oncologists, and primary care providers to manage symptoms and monitor disease progression.

Bernard-Soulier Syndrome

Definition

Bernard-Soulier Syndrome (BSS) is a rare autosomal recessive bleeding disorder characterized by a defect in platelet adhesion, leading to a tendency to bleed excessively.

Pathophysiology

The defect in the GPIb-IX-V complex affects platelet interaction with von Willebrand factor (vWF), which is crucial for platelet adhesion to the collagen of the subendothelial matrix.

Etiology

Caused by mutations in the genes coding for the platelet glycoproteins, primarily GPIb-IX-V complex, which impairs platelet adhesion to the subendothelial matrix.

Genetics

- Inherited in an autosomal recessive pattern.
- Commonly associated with mutations in the *GP1BA*, *GP1BB*, and *GP9* genes.

Clinical Features

- **Bleeding Symptoms:**
  - Easy bruising, petechiae, epistaxis, gingival bleeding, and menorrhagia.
  - Hemorrhagic episodes often occur spontaneously or following minor trauma.
- **Platelet Size:**
  - Presence of large platelets (macrothrombocytes) on blood smear.
- **Platelet Count:**
  - Typically normal to low, though bleeding symptoms are disproportionate to platelet count.

Diagnosis

Blood Smear:

- Microscopic examination reveals large platelets.

Platelet Function Tests:

- Prolonged bleeding time.
- Impaired platelet aggregation with ristocetin, which is corrected with the addition of von Willebrand factor.

Genetic Testing:

- Identification of mutations in *GP1BA*, *GP1BB*, or *GP9* genes.

Management

Bleeding Management:

- Treatment focuses on managing bleeding episodes and may involve platelet transfusions.

Preventive Measures:

- Avoidance of antiplatelet medications.
- Careful management during surgeries or invasive procedures.

Prognosis

- Variable depending on the severity of bleeding symptoms and response to treatment.
- Regular follow-up is required for managing bleeding risks and preventing complications.

Key Points

- Bernard-Soulier Syndrome is characterized by defective platelet adhesion due to abnormalities in the GPIb-IX-V complex.
- Diagnosis involves blood smear examination and platelet function tests.
- Management includes bleeding control and preventive strategies for bleeding complications.

Glanzmann's Thrombasthenia

Definition

Rare autosomal recessive bleeding disorder characterized by defective platelet aggregation due to the absence or dysfunction of platelet glycoprotein IIb/IIIa.

Etiology

Caused by mutations in the genes encoding glycoprotein IIb (ITGA2B) or glycoprotein IIIa (ITGB3), which are crucial components of the integrin complex responsible for platelet aggregation.

Pathophysiology

- Platelet glycoprotein IIb/IIIa complex (also known as integrin αIIbβ3) is essential for platelet aggregation by binding fibrinogen and other adhesive proteins.
- In Glanzmann's thrombasthenia, the complex is either absent or dysfunctional, leading to impaired platelet aggregation despite normal platelet count.

Clinical Features

- **Bleeding Manifestations:** Recurrent mucocutaneous bleeding, including easy bruising, epistaxis, gingival bleeding, menorrhagia, and gastrointestinal bleeding.
- **Severity:** Varies from mild to severe; bleeding tendencies may be exacerbated by trauma or surgery.

Diagnosis

- **Platelet Function Tests:** Platelet aggregation studies (e.g., aggregation in response to ADP, collagen, or thrombin) show reduced or absent aggregation.
- **Platelet Count:** Usually normal.
- **Platelet Morphology:** Normal.
- **Genetic Testing:** Confirmatory for mutations in ITGA2B or ITGB3 genes.

Management

- **Supportive Care:** Avoidance of medications that impair platelet function (e.g., aspirin, NSAIDs).
- **Bleeding Management:** Treatment of bleeding episodes may include platelet transfusions (although less effective due to underlying defect), and antifibrinolytic agents (e.g., tranexamic acid).
- **Prophylactic Measures:** Desmopressin (may help in some cases) and recombinant factor VIIa may be used in severe cases.

Prognosis

Varies with severity; regular follow-up with a hematologist is essential for managing bleeding risks and overall health.

Differential Diagnosis

- **Bernard-Soulier Syndrome:** Characterized by large platelets and impaired platelet aggregation but with absent or reduced expression of glycoprotein Ib-IX-V complex.
- **Other Platelet Function Disorders:** Such as storage pool disorders and other integrin-related disorders.

Key Points

- Glanzmann's thrombasthenia is a defect in platelet aggregation, not platelet number.
- Management involves careful bleeding control and avoidance of agents that worsen bleeding tendencies.

4 Coagulation Disorders

- Hemophilia
  - Hemophilia A (Factor VIII Deficiency)
  - Hemophilia B (Factor IX Deficiency)
- Von Willebrand Disease
  - Type 1
  - Type 2 (A, B, M, N)
  - Type 3
- Acquired Coagulation Disorders
  - Coagulation Disorders in Liver Disease
  - Vitamin K Deficiency
  - Coagulation Disorders due to Anticoagulant Therapy (Warfarin, Heparin)
- Thrombophilia
  - Factor V Leiden
  - Prothrombin Gene Mutation
  - Antithrombin Deficiency
  - Protein C and S Deficiency
  - Antiphospholipid Syndrome

Hemophilia A (Factor VIII Deficiency)

Definition

Hemophilia A is an X-linked recessive bleeding disorder characterized by a deficiency of clotting factor VIII, crucial for blood coagulation.

Epidemiology

- Most common type of hemophilia.
- Affects approximately 1 in 5,000 male births.
- Females can be carriers but are rarely affected.

Pathophysiology

- Factor VIII is a key component in the intrinsic pathway of the coagulation cascade.
- Deficiency leads to impaired fibrin clot formation and increased bleeding tendency.

Clinical Presentation

Bleeding Episodes:

- Spontaneous bleeding into joints (hemarthrosis) and muscles.
- Prolonged bleeding after surgery or trauma.
- Easy bruising.
- Nosebleeds and gum bleeding.

Severe Cases:

- Frequent and spontaneous bleeding episodes.
- Potential for life-threatening bleeds.

Diagnosis

Laboratory Tests:

- **Activated Partial Thromboplastin Time (aPTT):** Prolonged.
- **Prothrombin Time (PT):** Normal.
- **Factor VIII Activity Assay:** Reduced.
- **Factor VIII Inhibitor Assay:** Used to detect inhibitory antibodies.

Genetics

- **Inheritance:** X-linked recessive.
- **Gene:** F8 gene located on the X chromosome.
- **Mutation Types:** Can be point mutations, deletions, or insertions in the F8 gene.

Management

Factor Replacement Therapy:

- **Standard Half-Life Products:** Administered regularly to maintain factor levels.
- **Extended Half-Life Products:** Less frequent administration.

Desmopressin (DDAVP):

- Useful for mild cases or patients with type 1 hemophilia.
- Increases endogenous factor VIII levels.

Inhibitor Management:

- Use of bypassing agents like activated prothrombin complex concentrates (aPCC) or recombinant activated factor VII (rFVIIa).

Genetic Counseling:

- Important for family planning and understanding inheritance patterns.

Prognosis

- **Mild Hemophilia:** Good prognosis with appropriate treatment.
- **Severe Hemophilia:** Requires lifelong management; improved outcomes with advances in therapy.

Complications

- **Joint Damage:** Repeated hemarthrosis can lead to arthropathy.
- **Inhibitors:** Development of antibodies against factor VIII, complicating treatment.
- **Transfusion-Related Risks:** Risk of infections from blood products (mitigated by screening and factor concentrates).

Preventive Measures

- **Vaccinations:** Hepatitis B vaccination due to risk of bloodborne infections.
- **Dental Care:** Regular dental check-ups to minimize bleeding risks.

Hemophilia B (Factor IX Deficiency)

Definition

Hemophilia B, also known as Christmas disease, is a genetic bleeding disorder characterized by a deficiency in clotting factor IX, which is essential for blood coagulation.

Pathophysiology

- **Factor IX:** A vitamin K-dependent clotting factor produced in the liver.
- **Genetic Basis:** X-linked recessive inheritance; mutations in the F9 gene lead to defective or deficient factor IX.
- **Clotting Cascade:** Factor IX is crucial in the intrinsic pathway of the coagulation cascade, activating factor X which is essential for thrombin generation and fibrin formation.

Clinical Features

- **Bleeding Symptoms:** Includes spontaneous bleeding, prolonged bleeding after injuries, and easy bruising.
- **Hemarthrosis:** Common in joints, leading to pain and potential joint damage.
- **Muscle Bleeds:** Pain and swelling in muscles.
- **Other Sites:** May involve bleeding in the gastrointestinal tract, urinary tract, or intracranial hemorrhage.

Diagnosis

- **History and Physical Examination:** Assess bleeding history and family history of bleeding disorders.
- **Laboratory Tests:**
  - **Prothrombin Time (PT):** Usually normal.
  - **Activated Partial Thromboplastin Time (aPTT):** Prolonged.
  - **Factor IX Assay:** Low levels of factor IX confirm the diagnosis.
  - **Genetic Testing:** Identifies mutations in the F9 gene.

Classification

- **Mild:** Factor IX levels between 5-40% of normal.
- **Moderate:** Factor IX levels between 1-5% of normal.
- **Severe:** Factor IX levels <1% of normal, with frequent spontaneous bleeding.

Treatment

- **Factor IX Replacement Therapy:** The primary treatment, involving intravenous infusion of factor IX concentrates.
  - **Prophylaxis:** Regular infusions to prevent bleeding episodes.
  - **On-Demand Therapy:** Infusions given in response to bleeding episodes.
- **Recombinant Factor IX:** Genetically engineered factor IX products.
- **Gene Therapy:** Emerging treatment option aiming to provide long-term relief by correcting the genetic defect.

Management

- **Monitoring:** Regular assessment of factor IX levels and monitoring for bleeding complications.
- **Patient Education:** Emphasis on recognizing early signs of bleeding and appropriate response.
- **Physical Activity:** Avoidance of high-risk activities; physical therapy to maintain joint function.

Complications

- **Inhibitors:** Some patients may develop antibodies against factor IX, making treatment less effective.
- **Joint Damage:** Repeated bleeding into joints can lead to chronic pain and disability.

Prognosis

With appropriate treatment, individuals can lead a relatively normal life. Severe cases require ongoing management and monitoring to prevent and treat bleeding episodes effectively.

Von Willebrand Disease (VWD)

Overview

Von Willebrand Disease is the most common inherited bleeding disorder, characterized by defects in von Willebrand factor (vWF), which is crucial for platelet adhesion and clotting.

Types of Von Willebrand Disease

Type 1:

- **Description:** Mild deficiency in vWF.
- **Genetics:** Autosomal dominant.
- **Clinical Features:** Mucocutaneous bleeding, such as easy bruising and nosebleeds; bleeding after surgery or dental work.
- **Diagnosis:** Reduced vWF antigen and activity levels; normal factor VIII levels.

Type 2:

- **Description:** Qualitative defects in vWF. Subdivided into:
  - **Type 2A:**
    - **Description:** Impaired vWF multimer distribution and platelet binding.
    - **Clinical Features:** Similar to Type 1, with more severe bleeding episodes.
    - **Diagnosis:** Reduced large multimers of vWF.
  - **Type 2B:**
    - **Description:** Increased vWF-platelet binding leading to premature platelet clearance.
    - **Clinical Features:** Bleeding symptoms can be similar to Type 2A; risk of thrombocytopenia.
    - **Diagnosis:** Increased vWF-platelet binding in the presence of normal vWF levels.
  - **Type 2M:**
    - **Description:** Reduced platelet adhesion without significant multimer abnormalities.
    - **Clinical Features:** Bleeding symptoms may be less severe than Types 2A and 2B.
    - **Diagnosis:** Reduced vWF platelet-binding activity.
  - **Type 2N:**
    - **Description:** Deficiency in vWF's ability to bind factor VIII, leading to reduced factor VIII levels.
    - **Clinical Features:** Bleeding symptoms similar to hemophilia A.
    - **Diagnosis:** Normal vWF levels with reduced factor VIII levels.

Type 3:

- **Description:** Severe deficiency or absence of vWF.
- **Genetics:** Autosomal recessive.
- **Clinical Features:** Severe bleeding symptoms including joint and muscle bleeds, similar to hemophilia.
- **Diagnosis:** Very low or undetectable vWF antigen and activity levels; low factor VIII levels.

Management

- **Type 1 and 2:** Desmopressin (DDAVP) can be used to stimulate vWF release. In cases of severe bleeding or when DDAVP is ineffective, vWF concentrates may be necessary.
- **Type 3:** Requires vWF replacement therapy with vWF concentrates.

Monitoring

- Regular assessment of vWF antigen levels, activity assays, and factor VIII levels.
- Tailoring therapy to the specific type and severity of the disease.

Coagulation Disorders in Liver Disease

Overview

Liver disease significantly impacts the coagulation system due to the liver's central role in synthesizing clotting factors and regulating anticoagulant proteins. Coagulation disorders in liver disease are characterized by both bleeding and thrombotic tendencies.

Pathophysiology

- **Clotting Factors Production**: The liver synthesizes most of the coagulation factors, including Factors I (fibrinogen), II (prothrombin), V, VII, IX, and X. Liver dysfunction leads to decreased production of these factors.
- **Anticoagulant Proteins**: The liver also produces anticoagulants such as Protein C, Protein S, and Antithrombin III. Liver disease can reduce levels of these proteins, altering the balance between coagulation and anticoagulation.

Types of Liver Disease Affecting Coagulation

- **Acute Liver Failure**: Can lead to rapid deterioration in coagulation function.
- **Chronic Liver Disease**: Results in progressive and often less dramatic coagulation abnormalities.
- **Cirrhosis**: Commonly associated with both bleeding and thrombosis due to a complex interplay of factors.

Coagulation Profile Changes

- **Prothrombin Time (PT)**: Often prolonged due to reduced synthesis of clotting factors.
- **Activated Partial Thromboplastin Time (aPTT)**: Can be prolonged, reflecting deficiencies in factors VIII, IX, XI, and XII.
- **Platelet Count**: May be decreased due to splenomegaly or bone marrow suppression.
- **Fibrinogen Levels**: Can be normal or decreased. Low levels are indicative of severe liver dysfunction or disseminated intravascular coagulation (DIC).

Clinical Manifestations

- **Bleeding**: Common manifestations include gastrointestinal bleeding, easy bruising, and prolonged bleeding from minor injuries.
- **Thrombosis**: Risk of portal vein thrombosis, deep vein thrombosis (DVT), and pulmonary embolism due to altered balance of procoagulant and anticoagulant factors.

Management

- **Assessment**: Regular monitoring of PT, aPTT, platelet count, and fibrinogen levels.
- **Transfusion Therapy**: Fresh frozen plasma (FFP) or clotting factor concentrates can be used to correct severe coagulopathy.
- **Anticoagulant Use**: Caution is required with anticoagulant therapy; individual risk assessment is crucial.
- **Liver Disease Treatment**: Addressing the underlying liver condition can help improve coagulation abnormalities.

Summary

Coagulation disorders in liver disease are complex, involving both bleeding and thrombotic risks. Regular monitoring and appropriate treatment based on the specific coagulation profile are essential for managing these disorders effectively.

Vitamin K Deficiency

Overview

Vitamin K is essential for synthesizing clotting factors in the liver, specifically factors II, VII, IX, and X, as well as proteins C and S which are important for anticoagulation regulation.

Causes

- **Dietary Deficiency:** Rare in developed countries but can occur in malnourished individuals or those with poor dietary intake.
- **Malabsorption:** Conditions such as celiac disease, Crohn's disease, or chronic pancreatitis can impair vitamin K absorption.
- **Antibiotic Use:** Broad-spectrum antibiotics can disrupt gut flora, which is crucial for synthesizing vitamin K.
- **Liver Disease:** Since vitamin K is metabolized in the liver, liver dysfunction can affect its utilization.
- **Medication:** Warfarin, a vitamin K antagonist, can lead to deficiency if not properly monitored.

Clinical Features

- **Bleeding Tendency:** Easy bruising, bleeding gums, and nosebleeds.
- **Hemorrhagic Symptoms:** Gastrointestinal bleeding, hematuria, and in severe cases, intracranial hemorrhage.
- **Prolonged PT/INR:** Prothrombin time (PT) is prolonged due to decreased synthesis of clotting factors.

Diagnosis

- **Clinical Evaluation:** History of risk factors or symptoms of bleeding.
- **Laboratory Tests:**
  - **Prothrombin Time (PT):** Prolonged PT is a key indicator.
  - **Activated Partial Thromboplastin Time (aPTT):** May be normal or mildly prolonged.
  - **Vitamin K Levels:** Specific assays can confirm deficiency.

Management

- **Oral Vitamin K:** Administered for mild deficiencies or dietary insufficiency.
- **Intravenous Vitamin K:** Required in severe cases or when rapid correction is necessary.
- **Address Underlying Causes:** Treat malabsorption issues or adjust anticoagulant therapy as needed.
- **Monitoring:** Regularly check PT/INR to ensure appropriate correction of coagulation parameters.

Key Points

- Vitamin K deficiency leads to impaired synthesis of clotting factors, causing bleeding disorders.
- Diagnosis relies on clinical presentation and PT/INR levels.
- Treatment typically involves vitamin K supplementation and management of underlying conditions.

Prevention

- **Balanced Diet:** Ensure adequate intake of vitamin K through green leafy vegetables and other sources.
- **Prophylaxis in High-Risk Groups:** For patients on long-term antibiotics or anticoagulants, monitor and supplement vitamin K as necessary.

Coagulation Disorders Due to Anticoagulant Therapy

1. Warfarin (Coumadin)

- **Mechanism of Action**: Warfarin is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S in the liver.
- **Monitoring**: International Normalized Ratio (INR) is used to monitor efficacy and safety. Therapeutic INR ranges are typically 2.0-3.0 for most indications, but may vary.
- **Antidote**: Vitamin K (oral or intravenous) can reverse the effects of warfarin. In severe cases, prothrombin complex concentrates (PCC) or fresh frozen plasma (FFP) may be used.
- **Drug Interactions**: Numerous interactions with drugs and foods (e.g., green leafy vegetables, alcohol) can affect warfarin metabolism and INR.

Common Complications

- **Bleeding**: Increased risk of bleeding, including gastrointestinal bleeding and intracranial hemorrhage.
- **Warfarin-Induced Skin Necrosis**: Rare but serious condition occurring usually within the first few days of therapy, often related to protein C deficiency.
- **Purple Toe Syndrome**: Rare complication characterized by discoloration of the toes due to microemboli.

2. Heparin

- **Mechanism of Action**: Heparin enhances the activity of antithrombin III, which inactivates thrombin and factor Xa, preventing the formation of fibrin clots.
- **Types**:
  - **Unfractionated Heparin (UFH)**: Administered intravenously. Requires regular monitoring of Activated Partial Thromboplastin Time (aPTT).
  - **Low Molecular Weight Heparin (LMWH)**: Administered subcutaneously. Generally requires less frequent monitoring, often using Anti-Xa levels.
- **Antidote**: Protamine sulfate can reverse the effects of heparin. For LMWH, protamine sulfate has partial efficacy.
- **Monitoring**: Regular monitoring of aPTT for UFH and Anti-Xa levels for LMWH is necessary to ensure therapeutic efficacy and safety.

Common Complications

- **Bleeding**: Risk of major bleeding (e.g., in the gastrointestinal tract or brain).
- **Heparin-Induced Thrombocytopenia (HIT)**: An immune-mediated reaction causing thrombocytopenia and an increased risk of thrombosis.
- **Osteoporosis**: Long-term use of UFH can lead to bone density loss.

General Considerations

- **Risk Factors for Complications**: Patient factors such as renal or hepatic impairment, age, and concurrent use of other medications can influence the risk of bleeding and other complications.
- **Patient Education**: Patients should be informed about signs of bleeding, proper medication adherence, and interaction with foods and other drugs.

Factor V Leiden

Definition

A genetic mutation of the factor V gene that leads to a hypercoagulable state, increasing the risk of abnormal blood clotting.

Genetics

- Caused by a specific point mutation in the factor V gene (G1691A).
- Inherited in an autosomal dominant pattern.
- Individuals with one copy of the mutation are heterozygous, while those with two copies are homozygous.

Pathophysiology

- The mutation results in resistance to activated protein C (APC), a crucial anticoagulant.
- APC normally inactivates factor Va and factor VIIIa, thus limiting clot formation.
- Factor V Leiden mutation impairs this inactivation, leading to prolonged clotting and increased thrombotic risk.

Clinical Manifestations

- **Deep Vein Thrombosis (DVT):** Common in the legs.
- **Pulmonary Embolism (PE):** Can result from DVTs.
- **Recurrent pregnancy loss:** Potential association with stillbirth and preeclampsia.
- **Thrombophlebitis:** Inflammation of veins due to clots.

Diagnosis

- **Genetic Testing:** Confirmatory test for the presence of the Factor V Leiden mutation.
- **Activated Protein C Resistance Test:** Can indicate the presence of the mutation, though not specific.

Prognosis

- Individuals with the heterozygous mutation have a 5- to 10-fold increased risk of venous thrombosis.
- Homozygous individuals have a significantly higher risk, with a 30- to 100-fold increase.

Management

- **Anticoagulation Therapy:** For individuals with a history of thrombosis or at high risk.
- **Prophylaxis:** During surgery, prolonged immobilization, or pregnancy for those with a history of thrombosis.
- **Lifestyle Modifications:** Weight management, smoking cessation, and avoiding oral contraceptives if contraindicated.

Key Points

- Factor V Leiden is a common genetic cause of inherited thrombophilia.
- Risk of thrombosis is modifiable with appropriate anticoagulation and lifestyle changes.
- Genetic counseling may be beneficial for affected individuals and their families.

Prothrombin Gene Mutation

Definition

Prothrombin gene mutation refers to a genetic alteration in the prothrombin (F2) gene that leads to increased levels of prothrombin (factor II) in the blood, elevating the risk of thrombosis.

Prevalence: The G20210A mutation is the most common prothrombin gene mutation, found in about 1-2% of the general population.

Pathophysiology

- **Gene Involvement**: The mutation occurs in the prothrombin gene (F2) located on chromosome 11.
- **Mechanism**: The G20210A mutation leads to increased production of prothrombin, a precursor to thrombin, which in turn promotes excessive clot formation.

Clinical Significance

- **Risk of Thrombosis**: Individuals with the mutation have a 2-3 times higher risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).
- **Thrombosis Risk Factors**: Risk is further increased by other factors such as oral contraceptive use, pregnancy, surgery, and immobilization.

Diagnosis

- **Genetic Testing**: Confirmation of the mutation is typically done through molecular genetic testing, which identifies the presence of the G20210A mutation in the F2 gene.
- **Screening**: Testing is usually considered in patients with a history of unexplained thrombotic events, especially if they are young or have a family history of thrombosis.

Management

- **Acute Management**: Anticoagulant therapy (e.g., heparin, warfarin) is used for managing acute thrombotic events.
- **Long-Term Management**: Long-term anticoagulation may be recommended based on individual risk factors and history of thrombotic events.

Prevention

- **Lifestyle Modifications**: Patients are advised on lifestyle changes to reduce thrombotic risk, such as avoiding prolonged immobility.
- **Medication**: In certain high-risk scenarios, preventive anticoagulant therapy might be used.

Prognosis

Outlook: With appropriate management and preventive measures, individuals with the prothrombin gene mutation can often maintain a good quality of life and manage their thrombotic risk effectively.

Key Points

- **Prothrombin Gene Mutation (G20210A)** leads to increased risk of thrombotic events.
- **Genetic Testing** is essential for diagnosis.
- **Management** involves anticoagulation therapy and preventive strategies to reduce thrombotic risk.

Antithrombin Deficiency

Definition

Antithrombin (AT) deficiency is a genetic or acquired condition characterized by reduced levels or activity of antithrombin, a key inhibitor of blood clotting factors, primarily thrombin and factor Xa.

Types

1. **Type I:** Quantitative deficiency due to reduced production of antithrombin.
2. **Type II:** Qualitative deficiency with normal or near-normal levels but impaired function.

Etiology

Inherited:

- **Autosomal dominant inheritance**.
- Caused by mutations in the **SERPINC1** gene.
- Most common inherited thrombotic disorder.

Acquired:

- Occurs in conditions such as **liver disease**, **nephrotic syndrome**, **DIC**, and **post-surgical states**.

Clinical Features

Thrombosis:

- Increased risk of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism).
- Recurrent thrombotic events, often at a young age or in unusual locations.

Complications

- May lead to **heparin resistance** in patients undergoing anticoagulant therapy.

Diagnosis

Laboratory Tests:

- Measurement of antithrombin levels and activity.
- Functional assays often used for Type II deficiency.
- Genetic testing for definitive diagnosis of inherited cases.

Screening:

- Consider in patients with unexplained venous thrombosis or recurrent thrombosis.

Management

Anticoagulation Therapy:

- Long-term anticoagulation with drugs such as **warfarin** or **direct oral anticoagulants**.

Heparin Therapy:

- Special care required due to possible heparin resistance; alternative anticoagulants may be used.

Management of Underlying Conditions:

- Address any acquired causes or predisposing conditions.

Prognosis

With appropriate anticoagulation and management, individuals with antithrombin deficiency can have a relatively good prognosis, but they remain at higher risk for thrombotic events compared to the general population.

Key Points

- Antithrombin deficiency increases the risk of thrombotic events due to impaired regulation of coagulation factors.
- Both inherited and acquired forms exist, with specific management strategies for each.
- Regular monitoring and tailored anticoagulation therapy are crucial for managing the condition effectively.

Protein C and S Deficiency

Overview

- **Protein C and S** are vitamin K-dependent plasma proteins crucial for regulating coagulation.
- **Protein C**: Activated Protein C (APC) inactivates factors Va and VIIIa, which are critical for clot formation.
- **Protein S**: Serves as a cofactor for APC, enhancing its ability to inactivate coagulation factors.

Pathophysiology

- **Deficiency**: Both Protein C and S deficiencies lead to an increased risk of thrombotic events due to impaired regulation of coagulation.
- **Protein C Deficiency**: Results in a higher risk of venous thrombosis, especially in the deep veins of the legs (DVT) and pulmonary embolism (PE).
- **Protein S Deficiency**: Can present similarly to Protein C deficiency but also has a role in the prevention of thrombosis in both venous and arterial systems.

Causes

Genetic Deficiency:

- **Protein C**: Can be inherited in an autosomal dominant manner. Mutations in the PROC gene.
- **Protein S**: Inherited as autosomal dominant or recessive. Mutations in the PROS1 gene or reduced levels due to acquired conditions.

Acquired Deficiency:

- Conditions such as liver disease, Vitamin K deficiency, or the use of anticoagulants (e.g., warfarin) can also lower Protein C or S levels.

Clinical Presentation

- **Venous Thrombosis**: Most commonly observed in the deep veins of the legs.
- **Pulmonary Embolism**: Can occur due to dislodged clots from the veins.
- **Recurrent Thrombosis**: Increased risk for individuals with deficiencies.

Diagnosis

Laboratory Tests:

- **Protein C Activity**: Assesses functional levels.
- **Protein S Activity**: Functional assay of Protein S levels.
- **Genetic Testing**: Identifies mutations in PROC or PROS1 genes.
- **APC Resistance Test**: May indicate Protein C dysfunction.

Management

- **Anticoagulation Therapy**:
  - Long-term anticoagulants (e.g., warfarin, direct oral anticoagulants) to prevent thrombotic events.
- **Vitamin K Supplementation**: May be required in cases of Vitamin K deficiency.
- **Thrombosis Prevention**: Use of compression stockings, and addressing risk factors.

Prognosis

- With appropriate management, individuals with Protein C or S deficiency can have a good quality of life, though they need lifelong monitoring for thrombotic events.

Key Points

- Protein C and S deficiencies are significant risk factors for thrombosis.
- Genetic and acquired causes should be differentiated.
- Management primarily focuses on anticoagulation and prevention of thrombotic events.

Antiphospholipid Syndrome (APS)

Definition

Antiphospholipid Syndrome is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) and an increased risk of thrombosis (blood clots) and/or pregnancy complications.

Types

1. **Primary APS:** Occurs independently of other diseases.
2. **Secondary APS:** Associated with other autoimmune conditions, most commonly systemic lupus erythematosus (SLE).

Clinical Features

Thrombosis:

- **Venous Thrombosis:** Deep vein thrombosis (DVT), pulmonary embolism (PE).
- **Arterial Thrombosis:** Stroke, myocardial infarction, peripheral arterial disease.
- **Recurrent Thrombosis:** Multiple episodes of thrombosis.

Pregnancy Complications

- Recurrent miscarriages, especially in the second trimester.
- Preterm delivery due to preeclampsia or placental insufficiency.
- Fetal growth restriction.

Diagnostic Criteria

Clinical Criteria:

- One or more episodes of arterial, venous, or small vessel thrombosis.
- Pregnancy morbidity (e.g., unexplained fetal loss after 10 weeks of gestation, preterm delivery due to severe preeclampsia or placental insufficiency).

Laboratory Criteria:

- Presence of at least one of the following antiphospholipid antibodies:
  - **Lupus Anticoagulant (LA)**
  - **Anticardiolipin Antibodies (aCL):** IgG or IgM isotypes.
  - **Anti-β2 Glycoprotein I Antibodies (aβ2GPI):** IgG or IgM isotypes.
- Positive tests must be confirmed on two or more occasions, at least 12 weeks apart.

Pathophysiology

Antiphospholipid Antibodies: These antibodies interfere with the normal coagulation process by binding to phospholipid-binding proteins, leading to increased clot formation and a hypercoagulable state.

Management

Anticoagulation Therapy:

- **Initial Management:** Low molecular weight heparin (LMWH) or unfractionated heparin.
- **Long-Term Management:** Oral anticoagulants such as warfarin or direct oral anticoagulants (DOACs) (e.g., rivaroxaban, apixaban) based on individual risk assessment.

Pregnancy Management:

- Low-dose aspirin and heparin (LMWH) during pregnancy.
- Regular monitoring and management by a specialist in high-risk pregnancies.

Secondary Prevention:

- Management of associated conditions, such as lupus, if present.
- Lifestyle modifications to reduce thrombotic risk (e.g., smoking cessation, maintaining a healthy weight).

Prognosis

With appropriate treatment, many patients with APS can manage their condition effectively and reduce the risk of serious complications. However, ongoing monitoring and adherence to treatment are crucial for preventing thrombotic events and managing pregnancy-related risks.

Important Considerations

- **Differential Diagnosis:** Ensure differentiation from other causes of thrombosis or autoimmune diseases.
- **Monitoring:** Regular follow-up is essential to adjust treatment and monitor for potential side effects of anticoagulation therapy.

Summary

Antiphospholipid Syndrome is a serious condition that requires careful management to prevent thrombosis and complications, especially in pregnant women. Early diagnosis and appropriate treatment are key to improving outcomes and quality of life for affected individuals.

5 Bone Marrow Disorders

- Aplastic Anemia
- Myeloproliferative Disorders
  - Polycythemia Vera
  - Essential Thrombocythemia
  - Myelofibrosis
  - Chronic Myeloid Leukemia (CML)
- Myelodysplastic Syndromes (MDS)
- Paroxysmal Nocturnal Hemoglobinuria (PNH)

Aplastic Anemia

Definition

Aplastic anemia is a condition characterized by the failure of the bone marrow to produce adequate numbers of blood cells (red blood cells, white blood cells, and platelets), leading to pancytopenia (reduction in all three types of blood cells).

Causes

- **Primary (Idiopathic):** Most cases are idiopathic, with no identifiable cause.
- **Secondary Causes:**
  - **Autoimmune Disorders:** Systemic lupus erythematosus, rheumatoid arthritis.
  - **Infections:** Viral infections (e.g., hepatitis, HIV).
  - **Medications:** Chemotherapy, antibiotics, antiepileptics.
  - **Toxins:** Benzene, pesticides, radiation.
  - **Genetic Disorders:** Fanconi anemia, dyskeratosis congenita.

Pathophysiology

- **Bone Marrow Dysfunction:** The bone marrow fails to produce sufficient blood cells.
- **Autoimmune Destruction:** The immune system may target hematopoietic stem cells in the marrow.
- **Replacement by Fat:** Replacement of hematopoietic cells with fatty tissue.

Clinical Features

- **Anemia Symptoms:** Fatigue, pallor, shortness of breath.
- **Leukopenia Symptoms:** Recurrent infections, fever.
- **Thrombocytopenia Symptoms:** Easy bruising, bleeding (e.g., gum bleeding, petechiae).

Diagnosis

- **Complete Blood Count (CBC):** Shows pancytopenia.
- **Bone Marrow Aspiration/Biopsy:** Reveals hypocellular marrow with a decrease in hematopoietic cells and an increase in fatty tissue.
- **Reticulocyte Count:** Low.
- **Additional Tests:** Rule out secondary causes (e.g., liver function tests, viral markers, autoimmune panels).

Treatment

Supportive Care:

- **Blood Transfusions:** To manage anemia and thrombocytopenia.
- **Infection Control:** Antibiotics and antifungals for infections.

Immunosuppressive Therapy:

- **Antithymocyte Globulin (ATG):** To reduce immune system activity against bone marrow.
- **Cyclosporine:** To suppress immune response.

- **Bone Marrow Stimulation: Erythropoiesis-Stimulating Agents (ESAs)** may be used in certain cases.
- **Bone Marrow Transplant (BMT):** For severe cases or younger patients; involves replacing the defective marrow with healthy donor marrow.

Prognosis

- **Variable:** Depends on the severity, response to treatment, and presence of any underlying conditions.
- **Good Response to Treatment:** Patients may achieve remission or long-term management.
- **Poor Prognosis:** Severe cases or those with no response to treatment may have a lower survival rate.

Complications

- **Infections:** Due to neutropenia.
- **Hemorrhage:** Due to thrombocytopenia.
- **Secondary Malignancies:** Increased risk of developing other cancers.

Follow-Up

- Regular monitoring of blood counts.
- Surveillance for complications and secondary conditions.
- Long-term follow-up for patients who undergo BMT or receive prolonged immunosuppressive therapy.

Polycythemia Vera (PV)

Definition

A chronic myeloproliferative disorder characterized by an increase in red blood cell mass due to uncontrolled erythrocyte production.

Epidemiology

- Incidence: Rare, with an estimated prevalence of 2-3 cases per 100,000 people annually.
- More common in middle-aged adults, with a median age of diagnosis around 60 years.
- Slight male predominance.

Etiology

- **Primary PV:** Often due to a JAK2 (Janus kinase 2) gene mutation, specifically JAK2 V617F, found in approximately 95% of cases.
- **Secondary PV:** Can occur due to chronic hypoxia (e.g., from lung disease, high altitude) or tumors producing erythropoietin (e.g., renal cell carcinoma).

Pathophysiology

- Mutation in hematopoietic stem cells leads to clonal expansion of erythroid progenitor cells.
- Results in overproduction of red blood cells, and often white blood cells and platelets.
- Can cause increased blood viscosity and impaired blood flow.

Clinical Features

- **Symptoms:** Headache, dizziness, itching (especially after hot showers), fatigue, weight loss, abdominal fullness (due to splenomegaly).
- **Signs:** Ruddy complexion, splenomegaly, hepatomegaly, hypertension.
- **Complications:** Thrombosis (e.g., stroke, myocardial infarction), bleeding, gout, progression to myelofibrosis or acute myeloid leukemia.

Diagnosis

- **Laboratory Tests:**
  - Elevated hemoglobin/hematocrit levels.
  - Presence of JAK2 V617F mutation.
  - Low erythropoietin levels.
  - Bone marrow biopsy may show hypercellularity with increased erythroid, granulocytic, and megakaryocytic elements.
- **Differential Diagnosis:** Secondary erythrocytosis, essential thrombocythemia, myelofibrosis.

Treatment

- **Phlebotomy:** To maintain hematocrit levels below 45% in men and 42% in women.
- **Aspirin:** Low-dose to reduce thrombotic risk.
- **Cytoreductive Therapy:** Hydroxyurea or interferon-alpha for high-risk patients or those with resistant symptoms.
- **JAK2 Inhibitors:** Ruxolitinib for those with severe symptoms or resistance to conventional therapy.

Prognosis

Generally good with appropriate treatment, but the risk of thrombotic events and progression to more severe myeloproliferative disorders remains.

Monitoring

- Regular blood tests to monitor hematocrit levels and adjust treatment.
- Periodic assessment for complications and progression.

Key Points

- PV is a lifelong condition requiring ongoing management.
- Early diagnosis and treatment are crucial to prevent complications and improve quality of life.

Essential Thrombocythemia (ET)

Definition

A myeloproliferative neoplasm characterized by an elevated platelet count and increased risk of thrombosis or bleeding.

Complications

Risk of arterial and venous thrombosis, bleeding, and progression to myelofibrosis or acute leukemia.

Pathophysiology

- **Clonal Hematopoiesis:** Originates from a clonal proliferation of hematopoietic stem cells.
- **Genetic Mutations:** Frequently associated with JAK2 V617F mutation (in ~50% of cases), CALR mutations (in ~20-30% of cases), and MPL mutations (in ~5-10% of cases).

Diagnosis

- **Blood Tests:** Elevated platelet count (>450 x 10^9/L), normal red cell mass and white cell count.
- **Bone Marrow Biopsy:** Typically shows increased megakaryocytes with normal morphology.
- **Genetic Testing:** Detection of JAK2 V617F, CALR, or MPL mutations supports diagnosis.
- **Exclusion of Secondary Causes:** Rule out secondary causes of thrombocytosis (e.g., iron deficiency, infection, inflammation).

Clinical Features

- **Symptoms:** May be asymptomatic or present with symptoms related to thrombosis (e.g., stroke, myocardial infarction) or bleeding.
- **Physical Examination:** Splenomegaly is common; hepatomegaly and other findings are less frequent.

Diagnostic Criteria

1. **Elevated Platelet Count:** Persistent thrombocytosis (>450 x 10^9/L).
2. **Bone Marrow Findings:** Increased megakaryocytes with normal maturation.
3. **Exclusion of Other Myeloproliferative Neoplasms:** Absence of BCR-ABL1 fusion gene, and not meeting criteria for polycythemia vera or primary myelofibrosis.
4. **Genetic Mutation:** Presence of JAK2 V617F, CALR, or MPL mutations.

Management

- **Aspirin Therapy:** Low-dose aspirin is often used to reduce thrombotic risk.
- **Cytoreductive Therapy:** Considered in high-risk patients (e.g., hydroxyurea, interferon alpha).
- **Platelet-Reducing Agents:** Anagrelide may be used to reduce platelet count in some cases.
- **Monitoring:** Regular follow-up to monitor platelet counts and assess for complications.

Prognosis

- Generally, a good prognosis with appropriate management.
- Long-term risk of progression to myelofibrosis or acute leukemia is present but relatively low.

Summary

Essential Thrombocythemia is a chronic myeloproliferative disorder characterized by high platelet counts and potential thrombotic or hemorrhagic complications. Accurate diagnosis relies on clinical, laboratory, and genetic criteria. Management focuses on reducing thrombotic risk and controlling platelet levels.

Myelofibrosis

Definition

A rare myeloproliferative neoplasm characterized by the replacement of bone marrow with fibrous tissue.

Pathophysiology

- **Bone Marrow:** Replacement of hematopoietic tissue with collagenous fibrosis.
- **Hemopoiesis:** Extramedullary hematopoiesis in the spleen and liver due to ineffective bone marrow function.
- **Genetics:** Associated with mutations in JAK2, MPL, and CALR genes.

Clinical Features

Symptoms:

- Fatigue
- Weight loss
- Night sweats
- Fever
- Splenomegaly (common)
- Hepatomegaly

Signs:

- Anemia
- Thrombocytopenia or thrombocytosis
- Leukopenia or leukocytosis

Diagnosis

Blood Tests:

- Complete Blood Count (CBC): Anemia, leukocytosis, or leukopenia, thrombocytopenia or thrombocytosis.
- Peripheral Blood Smear: Leukoerythroblastic picture (presence of immature red and white blood cells).

Bone Marrow Biopsy:

- Hypercellularity with extensive fibrosis.

Genetic Testing:

- JAK2 V617F mutation is present in most cases.

Imaging:

- Ultrasound or CT scan of the abdomen to assess spleen and liver enlargement.

Treatment

Symptomatic Management:

- Blood transfusions for anemia.
- Erythropoiesis-stimulating agents.
- JAK2 inhibitors (e.g., ruxolitinib) for symptom control and disease modification.

Splenectomy:

- Considered in cases of massive splenomegaly causing significant symptoms.

Allogeneic Stem Cell Transplant:

- Considered in younger patients with high-risk disease.

Prognosis

- Variable; dependent on age, disease progression, and response to treatment.
- **Survival:** Median survival varies widely, but prognosis can be poor without effective treatment.

Complications

- **Secondary:** Increased risk of acute myeloid leukemia (AML) transformation.
- **Additional Issues:** Increased risk of thrombotic events and bleeding due to platelet dysfunction.

Follow-Up

- Regular monitoring of blood counts and symptoms.
- Periodic reassessment of treatment efficacy and side effects.

Chronic Myeloid Leukemia (CML)

Definition

Chronic Myeloid Leukemia (CML) is a type of cancer that originates in the bone marrow and affects the blood. It is characterized by the overproduction of myeloid cells, a type of white blood cell.

Epidemiology

- **Incidence:** Rare, accounting for about 15-20% of all leukemias in adults.
- **Age:** Primarily affects adults, with a peak incidence in the 5th to 6th decades of life.
- **Gender:** Slightly more common in men.

Pathophysiology

- **Genetic Mutation:** CML is associated with the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22, creating the BCR-ABL fusion gene.
- **BCR-ABL Fusion Protein:** This tyrosine kinase promotes cell proliferation and inhibits apoptosis, leading to the accumulation of myeloid cells.

Clinical Features

Symptoms:

- Fatigue
- Weight loss
- Night sweats
- Splenomegaly
- Hepatomegaly
- Abdominal pain or fullness

Laboratory Findings:

- Elevated white blood cell count with a high percentage of neutrophils and their precursors.
- Presence of basophils and eosinophils.
- Low platelet count may occur.

Diagnosis

- **Blood Smear:** Shows a high number of myeloid cells at various stages of maturation.
- **Bone Marrow Biopsy:** Hypercellularity with increased granulocyte precursors.
- **Cytogenetic Testing:** Detection of the Philadelphia chromosome and BCR-ABL fusion gene.

Stages

1. **Chronic Phase:**
   - Duration: Several years
   - Typically responds well to treatment.
2. **Accelerated Phase:**
   - Duration: Months
   - Increasing symptoms and lab abnormalities.
3. **Blast Crisis:**
   - Duration: Weeks
   - Resembles acute leukemia with high blast counts in blood and bone marrow.

Treatment

Tyrosine Kinase Inhibitors (TKIs):

- First-line treatment (e.g., Imatinib, Dasatinib, Nilotinib).
- Effective in targeting the BCR-ABL protein.

Chemotherapy:

- Used in cases where TKIs are not effective or in blast crisis.

Stem Cell Transplant:

- Considered for patients with accelerated phase or blast crisis, or those who do not respond to TKIs.

Prognosis

- **Chronic Phase:** Good prognosis with appropriate TKI therapy.
- **Accelerated/Blast Phase:** Worse prognosis, requiring more intensive treatment.

Monitoring

- **Regular Blood Tests:** To monitor response to treatment and disease progression.
- **Bone Marrow Biopsy:** To assess response to therapy and detect any transformation.

Complications

- **Disease Transformation:** To acute leukemia.
- **TKI Side Effects:** Nausea, fatigue, liver enzyme abnormalities.

Follow-up

- Regular monitoring for treatment efficacy and side effects.
- Assessment for potential disease progression or transformation.

Myelodysplastic Syndromes (MDS)

Definition

A group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, dysplasia in one or more myeloid cell lines, and a risk of transformation to acute myeloid leukemia (AML).

Etiology

- Primary (Idiopathic): Usually in older adults (median age ~70).
- Secondary: Resulting from prior chemotherapy, radiation, or environmental toxins (e.g., benzene).

Pathophysiology

- Bone marrow failure due to ineffective hematopoiesis and increased apoptosis.
- Clonal proliferation of abnormal myeloid progenitors.
- Risk of progression to AML.

Classification

Based on number of dysplastic lineages, cytopenias, and blast count.

- **Common subtypes:**
  - MDS with single-lineage dysplasia (MDS-SLD)
  - MDS with multilineage dysplasia (MDS-MLD)
  - MDS with excess blasts (MDS-EB)
  - MDS with isolated del(5q)

Clinical Features

- **Cytopenias**: Anemia (most common), neutropenia, thrombocytopenia.
- Symptoms of bone marrow failure: Fatigue, infections, easy bruising, and bleeding.
- Splenomegaly (in some cases).

Diagnosis

- **Peripheral Blood Smear**: Macrocytic or normocytic anemia, dysplastic features in white cells or platelets.
- **Bone Marrow Biopsy**: Hypercellular or hypocellular marrow with dysplastic myeloid precursors, blast count <20%.
- **Cytogenetics**: Chromosomal abnormalities (e.g., del(5q), -7/del(7q), +8).

Prognosis

- Varied based on subtype, cytogenetics, and blast count.
- **IPSS-R** (Revised International Prognostic Scoring System): Risk stratification based on cytopenias, bone marrow blasts, and cytogenetics.
- Survival ranges from months to years depending on risk category.

Management

- **Supportive Care**: Blood transfusions, erythropoiesis-stimulating agents, antibiotics for infections.
- **Disease-Modifying Therapies**:
  - Hypomethylating agents (e.g., azacitidine, decitabine).
  - Lenalidomide (especially in del(5q) MDS).
  - Hematopoietic stem cell transplantation (HSCT) for eligible patients.
- **Curative**: Allogeneic stem cell transplantation (only potential cure).

Complications

- Transformation to acute myeloid leukemia (AML).
- Refractory cytopenias, increased infection risk, bleeding.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Definition

PNH is a rare, acquired hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis, hemoglobinuria, and bone marrow failure.

Pathophysiology

- Mutation in the PIGA gene in hematopoietic stem cells.
- Deficiency of GPI-anchored proteins (CD55, CD59) on red blood cells, leading to complement-mediated destruction.
- Intravascular hemolysis results in hemoglobinuria, especially at night (due to acidosis during sleep).

Clinical Features

- **Hemolytic anemia**: Fatigue, pallor, dark urine (especially in the morning).
- **Thrombosis**: Venous thrombosis is a major cause of mortality (hepatic, cerebral, or abdominal veins).
- **Bone marrow failure**: Pancytopenia may develop.
- **Renal failure**: Due to chronic hemoglobinuria.
- **Smooth muscle dystonia**: Dysphagia, abdominal pain due to nitric oxide depletion.

Diagnosis

- **Flow cytometry**: Detects absence of CD55 and CD59 on RBCs and granulocytes.
- **Ham test** (rarely used now): Acidified serum test to trigger hemolysis.
- **Elevated LDH**, low haptoglobin, hemoglobinuria, elevated indirect bilirubin.

Complications

- **Thrombosis**: Leading cause of death.
- **Renal dysfunction**: From chronic hemoglobinuria.
- **Pulmonary hypertension**.

Key Points

- Chronic hemolysis and thrombosis are hallmarks.
- Flow cytometry is the gold standard for diagnosis.
- Eculizumab is a life-saving treatment option.

Treatment

- **Eculizumab**: A monoclonal antibody that inhibits terminal complement activation.
- **Ravulizumab**: A longer-acting complement inhibitor.
- **Supportive care**: Blood transfusions, iron supplements, anticoagulation for thrombosis.
- **Allogeneic bone marrow transplant**: In severe cases.

Prognosis

- Improved with complement inhibitors; however, the risk of thrombosis remains.

6 Hematologic Malignancies

- Leukemias (Explained in Chapter 2)
- Lymphomas (Explained in Chapter 2)
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms

Multiple Myeloma

Definition

A malignant plasma cell disorder characterized by clonal proliferation of plasma cells in the bone marrow, producing monoclonal immunoglobulins (paraproteins).

Epidemiology

- More common in older adults, median age of diagnosis: 65-70 years.
- Slight male predominance.
- Higher incidence in African descent.

Pathophysiology

- Clonal plasma cells produce excessive monoclonal proteins (IgG, IgA, rarely IgM or light chains).
- Increased bone marrow infiltration leads to bone destruction (lytic lesions) and impaired normal hematopoiesis.
- Overproduction of monoclonal proteins leads to organ damage (especially kidney) and hyperviscosity.

Clinical Features

- **Bone Pain**: Most common presenting symptom, especially in the back or ribs.
- **Fractures**: Pathological fractures due to lytic bone lesions.
- **Hypercalcemia**: Due to bone resorption.
- **Renal Failure**: From light chain cast nephropathy (myeloma kidney) or hypercalcemia.
- **Anemia**: Due to marrow infiltration and decreased erythropoiesis.
- **Infections**: Increased susceptibility due to immune suppression and decreased normal immunoglobulin production.

Diagnostic Criteria (CRAB)

- **C**: Calcium elevated (>11 mg/dL).
- **R**: Renal insufficiency (serum creatinine >2 mg/dL).
- **A**: Anemia (Hb <10 g/dL or 2 g/dL below normal).
- **B**: Bone lesions (lytic lesions, osteopenia, or fractures on imaging).

Investigations

Blood Tests:

- Complete blood count (anemia).
- Serum calcium, creatinine.
- Serum protein electrophoresis (SPEP) for monoclonal spike (M-protein).
- Serum free light chain assay.

Urine Tests:

- 24-hour urine for Bence Jones proteins.

Bone Marrow Biopsy:

- ≥10% clonal plasma cells.

Imaging:

- Skeletal survey, MRI, or PET-CT to assess bone lesions.

Staging (Revised International Staging System, R-ISS)

- Based on serum β2-microglobulin, albumin, LDH, and cytogenetic abnormalities.

Treatment

- **Initial Therapy**: Chemotherapy (e.g., bortezomib, lenalidomide, dexamethasone).
- **Autologous Stem Cell Transplant**: For eligible patients.
- **Bisphosphonates**: To manage bone disease (e.g., zoledronic acid).
- **Radiotherapy**: For localized bone pain or spinal cord compression.
- **Supportive Care**:
  - Manage renal failure, infections, hypercalcemia.

Prognosis

- Variable, median survival is 4-6 years with treatment.
- Prognosis depends on staging, genetic abnormalities, and response to treatment.

Myelodysplastic Syndromes (MDS)

Definition

A group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to cytopenias and dysplasia in one or more blood cell lines. It is a clonal bone marrow disorder and may progress to acute myeloid leukemia (AML).

Etiology

- **Primary (idiopathic):** Often seen in the elderly without a clear cause.
- **Secondary:** Associated with prior chemotherapy, radiation, or exposure to toxic chemicals (e.g., benzene).

Pathophysiology

- Clonal expansion of abnormal hematopoietic stem cells.
- Dysplastic changes in bone marrow cells.
- Ineffective hematopoiesis results in peripheral blood cytopenias.
- Potential evolution to AML due to genetic instability.

Clinical Features

- **Symptoms of cytopenias:**
  - Anemia: Fatigue, pallor, dyspnea.
  - Neutropenia: Recurrent infections.
  - Thrombocytopenia: Bleeding, petechiae, bruising.
- Often asymptomatic in early stages and detected incidentally.

Diagnosis

- **Complete Blood Count (CBC):** Shows one or more cytopenias (anemia, neutropenia, thrombocytopenia).
- **Peripheral blood smear:** Shows dysplastic features (e.g., macrocytic anemia, hypogranular neutrophils, abnormal platelet forms).
- **Bone marrow biopsy:**
  - Hypercellular or hypocellular marrow.
  - Dysplastic changes in hematopoietic cells.
  - Ringed sideroblasts (in some subtypes).
- **Cytogenetics:** May show chromosomal abnormalities (e.g., del(5q), monosomy 7).

Subtypes

1. **MDS with single lineage dysplasia.**
2. **MDS with multilineage dysplasia.**
3. **MDS with ring sideroblasts.**
4. **MDS with excess blasts (MDS-EB).**
5. **MDS with isolated del(5q).**
6. **MDS, unclassifiable.**

Management

- **Supportive care:**
  - Blood transfusions for anemia.
  - Growth factors (e.g., Erythropoiesis-stimulating agents).
  - Antibiotics for infections.
- **Disease-modifying therapy:**
  - Hypomethylating agents (e.g., azacitidine, decitabine).
  - Lenalidomide (especially for MDS with del(5q)).
- **Stem cell transplant:** The only potential cure, considered for younger patients with high-risk disease.
- **Experimental therapies and clinical trials** for newer agents.

Prognosis

- Varies depending on subtype, cytogenetics, and percentage of blasts in the bone marrow.
- **International Prognostic Scoring System (IPSS):** Used to predict prognosis based on cytogenetics, marrow blast percentage, and cytopenias.

Complications

- Progression to AML.
- Infection due to neutropenia.
- Bleeding due to thrombocytopenia.

Myeloproliferative Neoplasms (MPNs)

Definition

Myeloproliferative Neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders characterized by the overproduction of one or more types of mature blood cells. They include:

1. **Polycythemia Vera (PV)**
2. **Essential Thrombocythemia (ET)**
3. **Primary Myelofibrosis (PMF)**
4. **Chronic Myeloid Leukemia (CML)**

Common Pathophysiology

- Mutations in **JAK2**, **CALR**, or **MPL** genes leading to constitutive activation of signaling pathways that drive excessive cell proliferation.
- Increased risk of progression to myelofibrosis or transformation to acute leukemia.

Types

1. **Polycythemia Vera (PV)**:
   - **Characteristics**: Increased red blood cell mass, often associated with elevated white blood cells and platelets.
   - **Clinical Features**: Hyperviscosity, pruritus (especially after bathing), splenomegaly, risk of thrombosis.
   - **Diagnosis**: Elevated hemoglobin/hematocrit, low serum erythropoietin, JAK2 mutation.
   - **Treatment**: Phlebotomy, hydroxyurea, low-dose aspirin, JAK2 inhibitors.

2. **Essential Thrombocythemia (ET)**:
   - **Characteristics**: Sustained elevation in platelet count with no significant increase in red or white blood cells.
   - **Clinical Features**: Thrombosis or bleeding, splenomegaly, headache, erythromelalgia.
   - **Diagnosis**: Platelet count >450,000/μL, JAK2, CALR, or MPL mutations, exclusion of reactive thrombocytosis.
   - **Treatment**: Aspirin, hydroxyurea, anagrelide for high-risk patients.

3. **Primary Myelofibrosis (PMF)**:
   - **Characteristics**: Bone marrow fibrosis leading to cytopenias, extramedullary hematopoiesis.
   - **Clinical Features**: Splenomegaly, fatigue, weight loss, night sweats, anemia, bone pain.
   - **Diagnosis**: Leukoerythroblastic blood smear, bone marrow fibrosis, JAK2, CALR, or MPL mutations.
   - **Treatment**: Ruxolitinib (JAK2 inhibitor), blood transfusions, allogeneic stem cell transplant (in selected cases).

4. **Chronic Myeloid Leukemia (CML)**:
   - **Characteristics**: BCR-ABL fusion gene (Philadelphia chromosome), resulting in uncontrolled myeloid proliferation.
   - **Clinical Features**: Fatigue, weight loss, splenomegaly, elevated white blood cell count.
   - **Diagnosis**: Presence of BCR-ABL fusion gene by PCR or FISH.
   - **Treatment**: Tyrosine kinase inhibitors (e.g., imatinib), allogeneic stem cell transplant (in refractory cases).

Complications

- Thromboembolic events (PV, ET).
- Transformation to acute leukemia.
- Myelofibrosis progression (ET, PV).

Prognosis

- Highly variable depending on the specific MPN subtype and mutation status.
- PV and ET generally have a favorable prognosis with proper management, while PMF carries a worse prognosis due to progressive fibrosis and transformation risks.

Monitoring

- Regular CBC, bone marrow biopsy (if indicated), JAK2, CALR, MPL mutation tracking.
- Risk stratification based on age, history of thrombosis, and cytogenetic abnormalities.

7 Transfusion Medicine

- Transfusion Reactions
  - Hemolytic Transfusion Reactions
  - Febrile Non-Hemolytic Transfusion Reactions
  - Allergic Transfusion Reactions
  - Transfusion-Related Acute Lung Injury (TRALI)
  - Transfusion-Associated Circulatory Overload (TACO)
- Blood Component Therapy
  - Red Blood Cell Transfusion
  - Platelet Transfusion
  - Plasma Transfusion
  - Cryoprecipitate Transfusion

Hemolytic Transfusion Reactions

Definition

Hemolytic transfusion reactions (HTRs) occur when transfused red blood cells (RBCs) are destroyed by the recipient's immune system, either intravascularly or extravascularly.

Types

Acute Hemolytic Transfusion Reaction (AHTR):

- **Onset:** Within minutes to 24 hours after transfusion.
- **Mechanism:** ABO incompatibility, leading to complement activation and intravascular hemolysis.
- **Symptoms:** Fever, chills, hypotension, chest pain, back pain, dyspnea, hemoglobinuria, shock, disseminated intravascular coagulation (DIC), renal failure.
- **Management:** Immediate cessation of transfusion, supportive care, fluid resuscitation, and management of DIC or renal failure.

Delayed Hemolytic Transfusion Reaction (DHTR):

- **Onset:** Days to weeks after transfusion.
- **Mechanism:** Anamnestic response to non-ABO antibodies (e.g., Rh, Kell), causing extravascular hemolysis.
- **Symptoms:** Mild fever, jaundice, anemia, hemoglobinuria, indirect hyperbilirubinemia.
- **Management:** Supportive care, transfusion of antigen-negative blood for future transfusions.

Diagnosis

Lab Tests:

- Positive direct antiglobulin test (DAT/Coombs test)
- Increased lactate dehydrogenase (LDH)
- Decreased haptoglobin
- Hemoglobinuria
- Hyperbilirubinemia

Prevention

- Proper blood typing and cross-matching.
- Monitoring and screening for antibodies in high-risk patients (e.g., those with prior transfusions or pregnancies).

Complications

- Acute renal failure, DIC, shock, multiorgan failure (in severe AHTR).

Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)

Definition

FNHTRs are immune-mediated transfusion reactions characterized by fever and chills, occurring within 1-6 hours of transfusion, without hemolysis.

Pathophysiology

- Caused by recipient antibodies reacting to donor leukocytes or cytokines accumulated in stored blood products.
- Cytokine release (e.g., IL-1, IL-6, TNF) from leukocytes during blood storage is a major contributor.

Clinical Features

- Fever (rise in body temperature by ≥1°C or 2°F)
- Chills, rigors
- Mild dyspnea
- Headache, malaise

Diagnosis

- Exclusion of other transfusion reactions (e.g., hemolytic, septic, allergic)
- Negative direct antiglobulin test (DAT)
- Absence of hemolysis (normal haptoglobin, LDH, bilirubin)

Management

- Stop transfusion immediately.
- Administer antipyretics (e.g., acetaminophen).
- Monitor the patient closely.
- Rule out bacterial contamination or hemolysis.

Prevention

- Leukoreduction of blood products (removal of white blood cells).
- Use of fresher blood products to minimize cytokine buildup.

Prognosis

- Generally mild, self-limited, and non-life-threatening.
- Recurrence possible in future transfusions.

Key Points

- Most common transfusion reaction.
- Does not involve hemolysis or severe complications.
- Prevention strategies reduce incidence.

Allergic Transfusion Reactions

Definition

- Allergic reactions to blood transfusions are immune-mediated responses to plasma proteins or other components in transfused blood products.
- Can range from mild (urticaria) to severe (anaphylaxis).

Pathophysiology

- Immune response triggered by donor plasma proteins or other allergens in the transfused blood.
- In severe cases, IgA-deficient individuals can react to IgA in donor plasma.

Types

Mild Allergic Reaction:

- Characterized by itching, hives (urticaria), or rash.
- Occurs in 1-3% of transfusions.

Severe Allergic Reaction (Anaphylaxis):

- Rare but life-threatening.
- Symptoms include hypotension, bronchospasm, and angioedema.
- Associated with IgA deficiency or sensitivity to plasma proteins.

Clinical Features

- **Mild**: Itching, hives, erythema, flushing.
- **Severe**: Wheezing, hypotension, respiratory distress, shock.

Diagnosis

- Based on clinical presentation during or shortly after transfusion.
- Rule out other causes of transfusion reactions (e.g., hemolytic reactions, TRALI).

Management

Mild Reaction:

- Stop transfusion temporarily.
- Administer antihistamines (e.g., diphenhydramine).
- Resume transfusion once symptoms resolve.

Severe Reaction:

- Immediately stop transfusion.
- Administer epinephrine, corticosteroids, and antihistamines.
- Provide supportive care (oxygen, fluids).

Prevention

- Premedication with antihistamines for patients with a history of mild allergic reactions.
- Use of washed red blood cells or plasma-reduced components in individuals with recurrent or severe reactions, particularly in IgA deficiency.

Prognosis

- Mild reactions are self-limiting.
- Severe reactions, though rare, can be fatal if not treated promptly.

Transfusion-Related Acute Lung Injury (TRALI)

Definition

A serious, life-threatening complication of blood transfusion characterized by acute non-cardiogenic pulmonary edema occurring within 6 hours of transfusion.

Etiology

- Likely immune-mediated.
- Anti-HLA or anti-HNA (human neutrophil antigen) antibodies present in donor plasma react with recipient leukocytes, leading to neutrophil activation and lung injury.

Risk Factors

- Plasma-rich blood products (e.g., FFP, platelets).
- Multiparous female donors are more likely to have antibodies that can cause TRALI.

Clinical Features

- Acute onset of respiratory distress, dyspnea, hypoxemia.
- Bilateral pulmonary infiltrates on chest X-ray.
- Fever, hypotension, and tachycardia may be present.
- Symptoms typically occur within 1-2 hours of transfusion, up to a maximum of 6 hours.

Diagnosis

- Based on clinical presentation and exclusion of other causes of acute lung injury (e.g., volume overload, cardiac dysfunction, infections).
- Diagnostic criteria include acute onset of hypoxemia and new infiltrates on chest imaging without evidence of circulatory overload.

Management

- Immediate cessation of transfusion.
- Supportive care: oxygen supplementation, mechanical ventilation if required.
- Avoid diuretics as the mechanism is non-cardiogenic.
- Fluid management should be conservative.

Prevention

- Minimize unnecessary transfusions.
- Use male donor plasma or exclude multiparous females from plasma donation to reduce risk.

Prognosis

- Mortality rate ranges from 5-10%.
- Most patients recover with appropriate supportive care within 48-96 hours.

Differential Diagnosis

- Transfusion-associated circulatory overload (TACO).
- Acute respiratory distress syndrome (ARDS).
- Sepsis.

Transfusion-Associated Circulatory Overload (TACO)

Definition

TACO is a transfusion-related complication characterized by acute onset of circulatory overload due to excessive blood volume infused, leading to respiratory distress and heart failure.

Etiology

- Large volume transfusions or rapid transfusion rates.
- Underlying conditions: Cardiac, renal impairment, or elderly patients.
- Positive fluid balance (multiple transfusions in a short time).

Risk Factors

- Age extremes (elderly, infants).
- Pre-existing heart disease, chronic kidney disease (CKD).
- Multiple transfusions or rapid transfusions.
- Large volume of transfusion (especially plasma, platelets).

Clinical Features

- Dyspnea, orthopnea, cough.
- Hypertension, tachycardia.
- Jugular venous distension (JVD).
- Pulmonary edema (bilateral lung crackles).
- Hypoxemia (low oxygen saturation).
- Signs of heart failure (S3 gallop).

Diagnosis

- Clinical assessment of fluid overload.
- Chest X-ray: Pulmonary edema, cardiomegaly.
- Elevated brain natriuretic peptide (BNP).
- Echocardiogram: Cardiac dysfunction.

Prevention

- Slow transfusion rates, especially in high-risk patients.
- Pre-transfusion diuretics in at-risk patients.
- Monitor fluid status closely during transfusions.

Management

- Stop transfusion immediately.
- Oxygen therapy.
- Diuretics (e.g., furosemide) to reduce fluid overload.
- Supportive care: Fluid restriction.
- Monitor vitals and fluid balance.

Complications

- Acute respiratory distress syndrome (ARDS).
- Prolonged hospitalization.

Prognosis

- Most cases resolve with appropriate management, but severe cases can lead to significant morbidity.

Red Blood Cell (RBC) Transfusion

Indications

- Symptomatic anemia (e.g., fatigue, dyspnea, tachycardia).
- Acute blood loss with hemodynamic instability.
- Chronic anemia unresponsive to other treatments (e.g., refractory to iron, B12, or folate therapy).
- Hemoglobin threshold typically:
  - **<7 g/dL** for most patients.
  - **<8 g/dL** in patients with cardiovascular disease.
  - Tailored to individual clinical circumstances.

Preparation

- Blood typing and cross-matching (ABO and Rh compatibility).
- Leukoreduced blood is preferred to minimize febrile reactions and alloimmunization.
- Irradiated blood for immunocompromised patients to prevent graft-versus-host disease.

Administration

- One unit of packed RBCs typically raises hemoglobin by ~1 g/dL.
- Transfusion rate: 1-2 mL/kg/h (may be adjusted in cases of heart failure or fluid overload risk).
- Monitor for transfusion reactions (vital signs, symptoms of reaction).

Complications

- **Febrile Non-Hemolytic Transfusion Reaction**: Most common; due to cytokines or recipient antibodies against donor leukocytes.
- **Allergic Reactions**: Ranging from urticaria to anaphylaxis.
- **Hemolytic Transfusion Reactions**: Acute (ABO incompatibility) or delayed (minor antigen mismatch).
- **Transfusion-Related Acute Lung Injury (TRALI)**: Acute respiratory distress; immune-mediated.
- **Transfusion-Associated Circulatory Overload (TACO)**: Volume overload; dyspnea, hypertension.
- **Infection**: Rare; risk of transmission of viral infections (HIV, HBV, HCV) reduced by screening.

Alternatives

- Erythropoiesis-stimulating agents (ESAs) in chronic anemia.
- Iron, B12, or folate supplementation in deficiency states.

Special Considerations

- Patients with thalassemia or sickle cell anemia may require chronic transfusion.
- In cases of repeated transfusions, monitor for **iron overload** (secondary hemochromatosis).

Platelet Transfusion

Indications

- **Thrombocytopenia** with bleeding or high risk of bleeding
- **Prophylaxis** in patients with platelet count < 10,000/μL (to prevent spontaneous bleeding)
- **Surgical procedures** in patients with platelet count < 50,000/μL
- **Massive transfusion protocols** or **DIC** (disseminated intravascular coagulation)
- Platelet dysfunction (e.g., due to antiplatelet drugs)

Types of Platelet Products

- **Random Donor Platelets (RDP)**: Derived from whole blood donation. Each unit raises platelet count by 5,000–10,000/μL.
- **Single Donor Platelets (SDP)** (Apheresis): Collected by apheresis from a single donor. Each unit raises platelet count by 30,000–60,000/μL.

Dosing

- **Adult dose**: Typically 1 SDP or 4–6 units of RDP
- **Pediatric dose**: 5–10 mL/kg of body weight

Storage

- Stored at **20-24°C** with continuous agitation
- Shelf life: 5 days (risk of bacterial contamination increases with time)

Monitoring

- **Platelet count** 1 hour and 24 hours post-transfusion to assess response
- Clinical assessment of bleeding risk

Complications

- **Allergic reactions** (e.g., urticaria, anaphylaxis)
- **Febrile non-hemolytic transfusion reactions**
- **Bacterial contamination**
- **Transfusion-related acute lung injury (TRALI)**
- **Platelet refractoriness**: Poor increment post-transfusion, often due to alloimmunization or non-immune factors (e.g., splenomegaly, DIC)

Contraindications

- **Thrombotic thrombocytopenic purpura (TTP)**
- **Heparin-induced thrombocytopenia (HIT)** (unless life-threatening bleeding)

Plasma Transfusion

Definition

Plasma transfusion involves the administration of plasma, the liquid portion of blood containing water, proteins (mainly albumin), electrolytes, and clotting factors, to correct coagulation deficiencies or treat specific conditions.

Indications

- **Coagulopathy due to liver disease** – Plasma transfusion provides clotting factors.
- **Disseminated Intravascular Coagulation (DIC)** – Corrects clotting factor deficiencies.
- **Massive transfusion protocols** – Prevent dilutional coagulopathy.
- **Thrombotic Thrombocytopenic Purpura (TTP)** – Plasma exchange for replacing ADAMTS13 enzyme.
- **Warfarin reversal** – In life-threatening bleeding, when vitamin K reversal is insufficient.
- **Inherited clotting factor deficiencies** – When specific factor concentrates are unavailable.

Types of Plasma

- **Fresh Frozen Plasma (FFP)** – Plasma frozen within 8 hours of collection; contains all clotting factors.
- **Cryoprecipitate-poor plasma** – Plasma remaining after removal of cryoprecipitate; lacks fibrinogen, factor VIII, and von Willebrand factor.
- **Solvent/Detergent-treated Plasma** – Treated for pathogen reduction; used for immunocompromised patients.

Dosage

- Typical adult dose: 10–15 mL/kg body weight.
- Repeat doses may be required depending on the clinical situation and coagulation tests (PT/INR, aPTT).

Administration

- Plasma is thawed before transfusion.
- Infusion rate: Typically 10–20 mL/min; can be faster in emergencies.
- Compatibility testing: Plasma is ABO compatible with the recipient's red cells (no crossmatch required).

Risks & Complications

- **Allergic reactions** – From mild urticaria to anaphylaxis.
- **Transfusion-Related Acute Lung Injury (TRALI)** – Non-cardiogenic pulmonary edema.
- **Transfusion-Associated Circulatory Overload (TACO)** – Volume overload leading to heart failure.
- **Infections** – Rare due to screening and pathogen reduction.
- **Hypervolemia** – Due to large volumes required for effective coagulation factor replacement.

Monitoring

- Clinical response and coagulation parameters (PT, INR, aPTT) should be assessed post-transfusion.
- Monitor for signs of transfusion reactions or volume overload.

Contraindications

Plasma transfusion is not recommended for volume expansion or nutritional supplementation.

Cryoprecipitate Transfusion

Definition

Cryoprecipitate is a blood product derived from fresh frozen plasma (FFP) and contains concentrated clotting factors such as fibrinogen, Factor VIII, von Willebrand factor (vWF), and Factor XIII.

Composition

- Fibrinogen (~150-250 mg per unit)
- Factor VIII
- von Willebrand factor (vWF)
- Factor XIII
- Fibronectin

Indications

- **Hypofibrinogenemia**: Especially in conditions like disseminated intravascular coagulation (DIC) and massive transfusion.
- **Inherited Fibrinogen Deficiency**: Including congenital afibrinogenemia and dysfibrinogenemia.
- **Hemophilia A**: In certain situations where recombinant Factor VIII is unavailable.
- **von Willebrand Disease**: When specific vWF products are unavailable.
- **Factor XIII Deficiency**: Rare cases where Factor XIII concentrate is not available.

Dosage

- **Fibrinogen Replacement**: 1 unit of cryoprecipitate per 10 kg of body weight generally raises fibrinogen by 50-75 mg/dL.
- Typically, 10 units of cryoprecipitate are pooled for adult transfusion.

Administration

- **Compatibility**: ABO compatibility preferred but not mandatory.
- **Route**: Intravenous infusion over 30 minutes.
- **Monitoring**: Monitor fibrinogen levels after transfusion, especially in critical bleeding.

Special Considerations

- **Thawing**: Cryoprecipitate must be thawed before use and transfused within a limited time to maintain efficacy.
- **Storage**: Stored frozen, typically at -18°C or colder; once thawed, it should be used within 4-6 hours.

Side Effects

- **Allergic Reactions**: Mild to severe, including anaphylaxis.
- **Volume Overload**: Particularly in patients with heart or renal failure.
- **Infectious Risks**: Minimal with modern screening, but the potential for viral transmission exists.

Key Points

- Main use is to replace fibrinogen in bleeding patients or those at risk of bleeding.
- Cryoprecipitate is a rich source of multiple clotting factors.

Contraindications

- Cryoprecipitate should not be used as a volume expander or as a routine treatment in conditions where specific clotting factor concentrates are available (e.g., Factor VIII for Hemophilia A).

8 Hemoglobin Disorders

- **Thalassemias** (Explained in Chapter 1)
- **Sickle Cell Disease** (Explained in Chapter 1)
- **Hemoglobin C Disease** (Explained in Chapter 1)
- **Hemoglobin E Disease** (Explained in Chapter 1)